Escalation of Antimicrobial Resistance among Streptococcus pneumoniae: Implications for Therapy

ABSTRACT

Over the past 2 decades, antimicrobial resistance among Streptococcus pneumoniae, the most common cause of community-acquired pneumonia (CAP), has escalated dramatically worldwide. In the late 1970s, strains of pneumococci displaying resistance to penicillin were described in South Africa and Spain. By the early 1990s, penicillin-resistant clones of S. pneumoniae spread rapidly across Europe and globally. Additionally, resistance to macrolides and other antibiotic classes escalated in tandem with penicillin resistance. Six international clones (serotypes 6A, 6B, 9V, 14, 19F, 23F) were responsible for most of these resistant isolates. Currently, 20 to 30% of S. pneumoniae worldwide are multidrug resistant (MDR) (i.e., resistant to ≥ 3 different classes of antibiotics). Despite the dramatic escalation in the rate of antimicrobial resistance among pneumococci worldwide, the clinical impact of antimicrobial resistance is difficult to define. Treatment failures due to antibiotic-resistant pneumococci have been reported with meningitis, otitis media, and lower respiratory tract infections, but the relation between drug resistance and treatment failures has not been convincingly established. Clinical failures often reflect factors independent of antimicrobial susceptibility of the infecting organisms. Host factors (e.g., extremes of age; underlying immunosuppressive or debilitating disease; comorbidities), or factors that affect intrinsic virulence of the organisms (e.g., capsular subtype) strongly influence prognosis. Mortality rates are higher in the presence of multilobar involvement, renal insufficiency, need for intensive care unit (ICU) care, hypoxemia, severe derangement in physiological parameters, and comorbidities. Given these confounding factors, determining the impact of antimicrobial resistance on clinical outcomes is difficult, if not impossible. Prospective, randomized trials designed to assess the clinical significance of antimicrobial resistance among pneumococci are lacking, and for logistical reasons, will never be done. Does in vitro resistance translate into clinical failures? Should changing resistance patterns modify our choice of therapy for CAP or for suspected pneumococcal pneumonia? This review discusses several facets, including mechanisms of antimicrobial resistance among specific antibiotic classes, epidemiology and spread of antimicrobial resistance determinants regionally and worldwide, risk factors for acquisition and dissemination of resistance, the impact of key international clones displaying MDR, the clinical impact of antimicrobial resistance, and strategies to limit or curtail antimicrobial resistance among this key respiratory tract pathogen.

KEYWORDS

Streptococcus pneumoniae - pneumococcus - invasive pneumococcal disease (IPD) - antimicrobial resistance - penicillin resistance - macrolide resistance - fluoroquinolone resistance

REFERENCES

• 1 Klugman K P. Pneumococcal resistance to antibiotics.  Clin Microbiol Rev. 1990;  3 171-196
• 2 Appelbaum P C. World-wide development of antibiotic resistance in pneumococci.  Eur J Clin Microbiol. 1987;  6 367-377
• 3 Appelbaum P C. Antimicrobial resistance in Streptococcus pneumoniae: an overview.  Clin Infect Dis. 1992;  15 77-83
• 4 Doern G V, Richter S S, Miller A et al.. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes?.  Clin Infect Dis. 2005;  41 139-148
• 5 Jacobs M R, Koornhof H J, Robins-Browne R M et al.. Emergence of multiply resistant pneumococci.  N Engl J Med. 1978;  299 735-740
• 6 Hsieh Y C, Hsueh P R, Lu C Y, Lee P I, Lee C Y, Huang L M. Clinical manifestations and molecular epidemiology of necrotizing pneumonia and empyema caused by Streptococcus pneumoniae in children in Taiwan.  Clin Infect Dis. 2004;  38 830-835
• 7 Tomasz A. New faces of an old pathogen: emergence and spread of multidrug-resistant Streptococcus pneumoniae .  Am J Med. 1999;  107(1A) 55S-62S
• 8 Doern G V, Heilmann K P, Huynh H K, Rhomberg P R, Coffman S L, Brueggemann A B. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995.  Antimicrob Agents Chemother. 2001;  45 1721-1729
• 9 Doern G V, Brueggemann A B, Blocker M et al.. Clonal relationships among high-level penicillin-resistant Streptococcus pneumoniae in the United States.  Clin Infect Dis. 1998;  27 757-761
• 10 Doern G V, Brueggemann A B, Huynh H, Wingert E. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997-98.  Emerg Infect Dis. 1999;  5 757-765
• 11 Sa-Leao R, Tomasz A, de Lencastre H. Multilocus sequence typing of Streptococcus pneumoniae clones with unusual drug resistance patterns: genetic backgrounds and relatedness to other epidemic clones.  J Infect Dis. 2001;  184 1206-1210
• 12 Enright M C, Fenoll A, Griffiths D, Spratt B G. The three major Spanish clones of penicillin-resistant Streptococcus pneumoniae are the most common clones recovered in recent cases of meningitis in Spain.  J Clin Microbiol. 1999;  37 3210-3216
• 13 Richter S S, Heilmann K P, Coffman S L et al.. The molecular epidemiology of penicillin-resistant Streptococcus pneumoniae in the United States, 1994-2000.  Clin Infect Dis. 2002;  34 330-339
• 14 Klugman K P. The role of clonality in the global spread of fluoroquinolone-resistant bacteria.  Clin Infect Dis. 2003;  36 783-785
• 15 Doit C, Loukil C, Fitoussi F, Geslin P, Bingen E. Emergence in France of multiple clones of clinical Streptococcus pneumoniae isolates with high-level resistance to amoxicillin.  Antimicrob Agents Chemother. 1999;  43 1480-1483
• 16 Corso A, Severina E P, Petruk V F, Mauriz Y R, Tomasz A. Molecular characterization of penicillin-resistant Streptococcus pneumoniae isolates causing respiratory disease in the United States.  Microb Drug Resist. 1998;  4 325-337
• 17 Syrogiannopoulos G A, Grivea I N, Davies T A, Katopodis G D, Appelbaum P C, Beratis N G. Antimicrobial use and colonization with erythromycin-resistant Streptococcus pneumoniae in Greece during the first 2 years of life.  Clin Infect Dis. 2000;  31 887-893
• 18 Soares S, Kristinsson K G, Musser J M, Tomasz A. Evidence for the introduction of a multiresistant clone of serotype 6B Streptococcus pneumoniae from Spain to Iceland in the late 1980s.  J Infect Dis. 1993;  168 158-163
• 19 Whitney C G, Farley M M, Hadler J et al.. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States.  N Engl J Med. 2000;  343 1917-1924
• 20 Lynch I J, Martinez F J. Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia.  Clin Infect Dis. 2002;  34(Suppl 1) S27-S46
• 21 Farrell D J, Jenkins S G, Brown S D, Patel M, Lavin B S, Klugman K P. Emergence and spread of Streptococcus pneumoniae with erm(B) and mef(A) resistance.  Emerg Infect Dis. 2005;  11 851-858
• 22 McGee L, McDougal L, Zhou J et al.. Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the pneumococcal molecular epidemiology network.  J Clin Microbiol. 2001;  39 2565-2571
• 23 Klugman K. Pneumococcal molecular epidemiology network.  ASM News. 1998;  64 371
• 24 Sa-Leao R, Tomasz A, Sanches I S et al.. Carriage of internationally spread clones of Streptococcus pneumoniae with unusual drug resistance patterns in children attending day care centers in Lisbon, Portugal.  J Infect Dis. 2000;  182 1153-1160
• 25 Gasc A M, Geslin P, Sicard A M. Relatedness of penicillin-resistant Streptococcus pneumoniae serogroup 9 strains from France and Spain.  Microbiology. 1995;  141(Pt 3) 623-627
• 26 Tomasz A, Corso A, Severina E P et al.. Molecular epidemiologic characterization of penicillin-resistant Streptococcus pneumoniae invasive pediatric isolates recovered in six Latin-American countries: an overview. PAHO/Rockefeller University Workshop. Pan American Health Organization.  Microb Drug Resist. 1998;  4 195-207
• 27 Munoz R, Coffey T J, Daniels M et al.. Intercontinental spread of a multiresistant clone of serotype 23F Streptococcus pneumoniae .  J Infect Dis. 1991;  164 302-306
• 28 Song J H, Lee N Y, Ichiyama S et al.. Spread of drug-resistant Streptococcus pneumoniae in Asian countries: Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study.  Clin Infect Dis. 1999;  28 1206-1211
• 29 Kristinsson K G. Modification of prescribers' behavior: the Icelandic approach.  Clin Microbiol Infect. 1999;  5(Suppl 4) S43-S7
• 30 Sa-Leao R, Vilhelmsson S E, de Lencastre H, Kristinsson K G, Tomasz A. Diversity of penicillin-nonsusceptible Streptococcus pneumoniae circulating in Iceland after the introduction of penicillin-resistant clone Spain(6B)-2.  J Infect Dis. 2002;  186 966-975
• 31 Vilhelmsson S E, Tomasz A, Kristinsson K G. Molecular evolution in a multidrug-resistant lineage of Streptococcus pneumoniae: emergence of strains belonging to the serotype 6B Icelandic clone that lost antibiotic resistance traits.  J Clin Microbiol. 2000;  38 1375-1381
• 32 Shi Z Y, Enright M C, Wilkinson P, Griffiths D, Spratt B G. Identification of three major clones of multiply antibiotic-resistant Streptococcus pneumoniae in Taiwanese hospitals by multilocus sequence typing.  J Clin Microbiol. 1998;  36 3514-3519
• 33 Hsueh P R, Luh K T. Antimicrobial resistance in Streptococcus pneumoniae, Taiwan.  Emerg Infect Dis. 2002;  8 1487-1491
• 34 Ho P L, Yam W C, Cheung T K et al.. Fluoroquinolone resistance among Streptococcus pneumoniae in Hong Kong linked to the Spanish 23F clone.  Emerg Infect Dis. 2001;  7 906-908
• 35 Gherardi G, Whitney C G, Facklam R R, Beall B. Major related sets of antibiotic-resistant pneumococci in the United States as determined by pulsed-field gel electrophoresis and pbp1a-pbp2b-pbp2x-dhf restriction profiles.  J Infect Dis. 2000;  181 216-229
• 36 Hermans P, Overweg K, Sjuijter M, deGroot R. Penicillin-resistant Streptococcus pneumoniae: an international molecular epidemiological study. In: Tomasz A Streptococcus pneumoniae Molecular Biology and Mechanisms of Disease. Larchmont, NY; Mary Ann Liebert 2000: 457-466
• 37 Granizo J J, Aguilar L, Casal J, Garcia-Rey C, Dal-Re R, Baquero F. Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and beta-lactam consumption in Spain (1979-1997).  J Antimicrob Chemother. 2000;  46 767-773
• 38 Dowson C G, Coffey T J, Kell C, Whiley R A. Evolution of penicillin resistance in Streptococcus pneumoniae: the role of Streptococcus mitis in the formation of a low affinity PBP2B in S. pneumoniae .  Mol Microbiol. 1993;  9 635-643
• 39 Latini L, Ronchetti M P, Merolla R et al.. Prevalence of mefE, erm and tet(M) genes in Streptococcus pneumoniae strains from central Italy.  Int J Antimicrob Agents. 1999;  13 29-33
• 40 Gay K, Baughman W, Miller Y et al.. The emergence of Streptococcus pneumoniae resistant to macrolide antimicrobial agents: a 6-year population-based assessment.  J Infect Dis. 2000;  182 1417-1424
• 41 Lee H J, Park J Y, Jang S H, Kim J H, Kim E C, Choi K W. High incidence of resistance to multiple antimicrobials in clinical isolates of Streptococcus pneumoniae from a university hospital in Korea.  Clin Infect Dis. 1995;  20 826-835
• 42 Raz R, Elhanan G, Shimoni Z et al.. Pneumococcal bacteremia in hospitalized Israeli adults: epidemiology and resistance to penicillin. Israeli Adult Pneumococcal Bacteremia Group.  Clin Infect Dis. 1997;  24 1164-1168
• 43 Reichler M R, Rakovsky J, Slacikova M et al.. Spread of multidrug-resistant Streptococcus pneumoniae among hospitalized children in Slovakia.  J Infect Dis. 1996;  173 374-379
• 44 Widdowson C A, Klugman K P. Emergence of the M phenotype of erythromycin-resistant pneumococci in South Africa.  Emerg Infect Dis. 1998;  4 277-281
• 45 Kresken M, Henrichfreise B, Bagel S, Brauers J, Wiedemann B. High prevalence of the ermB gene among erythromycin-resistant Streptococcus pneumoniae isolates in Germany during the winter of 2000-2001 and in vitro activity of telithromycin.  Antimicrob Agents Chemother. 2004;  48 3193-3195
• 46 Brown S D, Farrell D J, Morrissey I. Prevalence and molecular analysis of macrolide and fluoroquinolone resistance among isolates of Streptococcus pneumoniae collected during the 2000-2001 PROTEKT US Study.  J Clin Microbiol. 2004;  42 4980-4987
• 47 Alou L, Ramirez M, Garcia-Rey C, Prieto J, de Lencastre H. Streptococcus pneumoniae isolates with reduced susceptibility to ciprofloxacin in Spain: clonal diversity and appearance of ciprofloxacin-resistant epidemic clones.  Antimicrob Agents Chemother. 2001;  45 2955-2957
• 48 Nichol K A, Zhanel G G, Hoban D J. Molecular epidemiology of penicillin-resistant and ciprofloxacin-resistant Streptococcus pneumoniae in Canada.  Antimicrob Agents Chemother. 2003;  47 804-808
• 49 Johnson C N, Benjamin Jr W H, Moser S A et al.. Genetic relatedness of levofloxacin-nonsusceptible Streptococcus pneumoniae isolates from North America.  J Clin Microbiol. 2003;  41 2458-2464
• 50 Davies T A, Goldschmidt R, Pfleger S et al.. Cross-resistance, relatedness and allele analysis of fluoroquinolone-resistant US clinical isolates of Streptococcus pneumoniae (1998-2000).  J Antimicrob Chemother. 2003;  52 168-175
• 51 Weiss K, Restieri C, Gauthier R et al.. A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae .  Clin Infect Dis. 2001;  33 517-522
• 52 de la Campa A G, Balsalobre L, Ardanuy C, Fenoll A, Perez-Trallero E, Linares J. Fluoroquinolone resistance in penicillin-resistant Streptococcus pneumoniae clones, Spain.  Emerg Infect Dis. 2004;  10 1751-1759
• 53 Pletz M W, McGee L, Jorgensen J et al.. Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine.  Antimicrob Agents Chemother. 2004;  48 3491-3497
• 54 Clavo-Sanchez A J, Giron-Gonzalez J A, Lopez-Prieto D et al.. Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: a multicenter study.  Clin Infect Dis. 1997;  24 1052-1059
• 55 Pallares R, Gudiol F, Linares J et al.. Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci.  N Engl J Med. 1987;  317 18-22
• 56 Nava J M, Bella F, Garau J et al.. Predictive factors for invasive disease due to penicillin-resistant Streptococcus pneumoniae: a population-based study.  Clin Infect Dis. 1994;  19 884-890
• 57 Fairchok M P, Ashton W S, Fischer G W. Carriage of penicillin-resistant pneumococci in a military population in Washington, DC: risk factors and correlation with clinical isolates.  Clin Infect Dis. 1996;  22 966-972
• 58 Deeks S L, Palacio R, Ruvinsky R et al.. Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pneumoniae. The Streptococcus pneumoniae Working Group.  Pediatrics. 1999;  103 409-413
• 59 Choi E H, Lee H J. Clinical outcome of invasive infections by penicillin-resistant Streptococcus pneumoniae in Korean children.  Clin Infect Dis. 1998;  26 1346-1354
• 60 Vanderkooi O G, Low D E, Green K, Powis J E, McGeer A. Predicting antimicrobial resistance in invasive pneumococcal infections.  Clin Infect Dis. 2005;  40 1288-1297
• 61 Albrich W C, Monnet D L, Harbarth S. Antibiotic selection pressure and resistance in Streptococcus pneumoniae and Streptococcus pyogenes .  Emerg Infect Dis. 2004;  10 514-517
• 62 Baquero F. Evolving resistance patterns of Streptococcus pneumoniae: a link with long-acting macrolide consumption?.  J Chemother. 1999;  11(Suppl 1) 35-43
• 63 Cizman M, Pokorn M, Seme K, Paragi M, Orazem A. Influence of increased macrolide consumption on macrolide resistance of common respiratory pathogens.  Eur J Clin Microbiol Infect Dis. 1999;  18 522-524
• 64 Pihlajamaki M, Kotilainen P, Kaurila T, Klaukka T, Palva E, Huovinen P. Macrolide-resistant Streptococcus pneumoniae and use of antimicrobial agents.  Clin Infect Dis. 2001;  33 483-488
• 65 Chen D K, McGeer A, de Azavedo J C, Low D E. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.  N Engl J Med. 1999;  341 233-239
• 66 Bhavnani S M, Hammel J P, Jones R N, Ambrose P G. Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States.  Diagn Microbiol Infect Dis. 2005;  51 31-37
• 67 Klugman K P, Koornhof H J, Friedland I R. Antibiotic resistance in pneumococcal meningitis.  Lancet. 1992;  340 437-438
• 68 Appelbaum P C. Resistance among Streptococcus pneumoniae: implications for drug selection.  Clin Infect Dis. 2002;  34 1613-1620
• 69 Appelbaum P C. Epidemiology and in vitro susceptibility of drug-resistant Streptococcus pneumoniae .  Pediatr Infect Dis J. 1996;  15 932-934
• 70 Mufson M A, Stanek R J. Bacteremic pneumococcal pneumonia in one American city: a 20-year longitudinal study, 1978-1997.  Am J Med. 1999;  107(1A) 34S-43S
• 71 Rahav G, Toledano Y, Engelhard D et al.. Invasive pneumococcal infections: a comparison between adults and children.  Medicine (Baltimore). 1997;  76 295-303
• 72 Waterer G W, Buckingham S C, Kessler L A, Quasney M W, Wunderink R G. Decreasing beta-lactam resistance in pneumococci from the Memphis region: analysis of 2152 isolates from 1996 to 2001.  Chest. 2003;  124 519-525
• 73 Quagliarello V J, Scheld W M. Treatment of bacterial meningitis.  N Engl J Med. 1997;  336 708-716
• 74 Catalan M J, Fernandez J M, Vazquez A, Varela de Seijas E, Suarez A, Bernaldo de Quiros J C. Failure of cefotaxime in the treatment of meningitis due to relatively resistant Streptococcus pneumoniae .  Clin Infect Dis. 1994;  18 766-769
• 75 Sloas M M, Barrett F F, Chesney P J et al.. Cephalosporin treatment failure in penicillin- and cephalosporin-resistant Streptococcus pneumoniae meningitis.  Pediatr Infect Dis J. 1992;  11 662-666
• 76 Dagan R, Abramson O, Leibovitz E et al.. Bacteriologic response to oral cephalosporins: are established susceptibility breakpoints appropriate in the case of acute otitis media?.  J Infect Dis. 1997;  176 1253-1259
• 77 del Castillo F, Baquero-Artigao F, Garcia-Perea A. Influence of recent antibiotic therapy on antimicrobial resistance of Streptococcus pneumoniae in children with acute otitis media in Spain.  Pediatr Infect Dis J. 1998;  17 94-97
• 78 Jacobs M R. Increasing importance of antibiotic-resistant Streptococcus pneumoniae in acute otitis media.  Pediatr Infect Dis J. 1996;  15 940-943
• 79 Poole M D. Otitis media complications and treatment failures: implications of pneumococcal resistance.  Pediatr Infect Dis J. 1995;  14(Suppl 4) S23-S26
• 80 Feikin D R, Schuchat A, Kolczak M et al.. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997.  Am J Public Health. 2000;  90 223-229
• 81 Metlay J P, Hofmann J, Cetron M S et al.. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia.  Clin Infect Dis. 2000;  30 520-528
• 82 Pallares R, Linares J, Vadillo M et al.. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain.  N Engl J Med. 1995;  333 474-480
• 83 Watanabe H, Sato S, Kawakami K et al.. A comparative clinical study of pneumonia by penicillin-resistant and -sensitive Streptococcus pneumoniae in a community hospital.  Respirology. 2000;  5 59-64
• 84 Yu V L, Chiou C C, Feldman C et al.. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome.  Clin Infect Dis. 2003;  37 230-237
• 85 Lonks J R, Durkin M R, Meyerhoff A N, Medeiros A A. Meningitis due to ceftriaxone-resistant Streptococcus pneumoniae .  N Engl J Med. 1995;  332 893-894
• 86 Lonks J R, Garau J, Gomez L et al.. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae .  Clin Infect Dis. 2002;  35 556-564
• 87 Waterer G W, Wunderink R G, Jones C B. Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy.  Chest. 2000;  118 1839-1840
• 88 Kelley M A, Weber D J, Gilligan P, Cohen M S. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin.  Clin Infect Dis. 2000;  31 1008-1011
• 89 Fogarty C, Goldschmidt R, Bush K. Bacteremic pneumonia due to multidrug-resistant pneumococci in three patients treated unsuccessfully with azithromycin and successfully with levofloxacin.  Clin Infect Dis. 2000;  31 613-615
• 90 Lonks J R. What is the clinical impact of macrolide resistance?.  Curr Infect Dis Rep. 2004;  6 7-12
• 91 Low D E. Quinolone resistance among pneumococci: therapeutic and diagnostic implications.  Clin Infect Dis. 2004;  38(Suppl 4) S357-S362
• 92 Low D E. Fluoroquinolone-resistant pneumococci: maybe resistance isn't futile?.  Clin Infect Dis. 2005;  40 236-238
• 93 Davidson R, Cavalcanti R, Brunton J L et al.. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.  N Engl J Med. 2002;  346 747-750
• 94 Urban C, Rahman N, Zhao X et al.. Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy.  J Infect Dis. 2001;  184 794-798
• 95 Ewig S, Ruiz M, Torres A et al.. Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae .  Am J Respir Crit Care Med. 1999;  159 1835-1842
• 96 Aspa J, Rajas O, Rodriguez de Castro F et al.. Drug-resistant pneumococcal pneumonia: clinical relevance and related factors.  Clin Infect Dis. 2004;  38 787-798
• 97 Henriques B, Kalin M, Ortqvist A et al.. Molecular epidemiology of Streptococcus pneumoniae causing invasive disease in five countries.  J Infect Dis. 2000;  182 833-839
• 98 Song J H, Jung S I, Ki H K et al.. Clinical outcomes of pneumococcal pneumonia caused by antibiotic-resistant strains in Asian countries: a study by the Asian Network for Surveillance of Resistant Pathogens.  Clin Infect Dis. 2004;  38 1570-1578
• 99 Friedland I R. Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease.  Pediatr Infect Dis J. 1995;  14 885-890
• 100 Baddour L M, Yu V L, Klugman K P et al.. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia.  Am J Respir Crit Care Med. 2004;  170 440-444
• 101 Turett G S, Blum S, Fazal B A, Justman J E, Telzak E E. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence.  Clin Infect Dis. 1999;  29 321-327
• 102 Karlowsky J A, Thornsberry C, Jones M E, Evangelista A T, Critchley I A, Sahm D F. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002).  Clin Infect Dis. 2003;  36 963-970
• 103 Rieux V, Carbon C, Azoulay-Dupuis E. Complex relationship between acquisition of beta-lactam resistance and loss of virulence in Streptococcus pneumoniae .  J Infect Dis. 2001;  184 66-72
• 104 Johnson C N, Briles D E, Benjamin Jr W H, Hollingshead S K, Waites K B. Relative fitness of fluoroquinolone-resistant Streptococcus pneumoniae .  Emerg Infect Dis. 2005;  11 814-820
• 105 Gillespie S H. Antibiotic resistance in the absence of selective pressure.  Int J Antimicrob Agents. 2001;  17 171-176
• 106 Gillespie S H, Voelker L L, Dickens A. Evolutionary barriers to quinolone resistance in Streptococcus pneumoniae .  Microb Drug Resist. 2002;  8 79-84
• 107 Kim J O, Weiser J N. Association of intrastrain phase variation in quantity of capsular polysaccharide and teichoic acid with the virulence of Streptococcus pneumoniae .  J Infect Dis. 1998;  177 368-377
• 108 Tuomanen E I, Austrian R, Masure H R. Pathogenesis of pneumococcal infection.  N Engl J Med. 1995;  332 1280-1284
• 109 Smith A M, Feldman C, Massidda O, McCarthy K, Ndiweni D, Klugman K P. Altered PBP 2A and its role in the development of penicillin, cefotaxime, and ceftriaxone resistance in a clinical isolate of Streptococcus pneumoniae .  Antimicrob Agents Chemother. 2005;  49 2002-2007
• 110 Maisnier-Patin S, Berg O G, Liljas L, Andersson D I. Compensatory adaptation to the deleterious effect of antibiotic resistance in Salmonella typhimurium .  Mol Microbiol. 2002;  46 355-366
• 111 Nilsson A I, Berg O G, Aspevall O, Kahlmeter G, Andersson D I. Biological costs and mechanisms of fosfomycin resistance in Escherichia coli .  Antimicrob Agents Chemother. 2003;  47 2850-2858
• 112 Standards NCoCL .Performance standards for antimicrobial susceptibility testing. Tenth informational supplement, M100-S11. National Committee for Clinical Laboratory Standards 2001
• 113 Coffey T J, Daniels M, McDougal L K, Dowson C G, Tenover F C, Spratt B G. Genetic analysis of clinical isolates of Streptococcus pneumoniae with high-level resistance to expanded-spectrum cephalosporins.  Antimicrob Agents Chemother. 1995;  39 1306-1313
• 114 Asahi Y, Takeuchi Y, Ubukata K. Diversity of substitutions within or adjacent to conserved amino acid motifs of penicillin-binding protein 2X in cephalosporin-resistant Streptococcus pneumoniae isolates.  Antimicrob Agents Chemother. 1999;  43 1252-1255
• 115 Kosowska K, Jacobs M R, Bajaksouzian S, Koeth L, Appelbaum P C. Alterations of penicillin-binding proteins 1A, 2X, and 2B in Streptococcus pneumoniae isolates for which amoxicillin MICs are higher than penicillin MICs.  Antimicrob Agents Chemother. 2004;  48 4020-4022
• 116 Jacobs M R, Bajaksouzian S, Zilles A, Lin G, Pankuch G A, Appelbaum P C. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study.  Antimicrob Agents Chemother. 1999;  43 1901-1908
• 117 Jacobs M R, Felmingham D, Appelbaum P C, Gruneberg R N. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents.  J Antimicrob Chemother. 2003;  52 229-246
• 118 Sahm D F, Thornsberry C, Mayfield D C, Jones M E, Karlowsky J A. In vitro activities of broad-spectrum cephalosporins against nonmeningeal isolates of Streptococcus pneumoniae: MIC interpretation using NCCLS M100-S12 recommendations.  J Clin Microbiol. 2002;  40 669-674
• 119 Ruhe J J, Myers L, Mushatt D, Hasbun R. High-level penicillin-nonsusceptible Streptococcus pneumoniae bacteremia: identification of a low-risk subgroup.  Clin Infect Dis. 2004;  38 508-514
• 120 Hansman D, Bullen M. A resistant pneumococcus.  Lancet. 1967;  1 264-265
• 121 Hansman D, Glasgow H, Sturt J, Devitt L, Douglas R. Increased resistance to penicillin of pneumococci isolated from man.  N Engl J Med. 1971;  284 175-177
• 122 Naraqi S, Kirkpatrick G P, Kabins S. Relapsing pneumococcal meningitis: isolation of an organism with decreased susceptibility to penicillin G.  J Pediatr. 1974;  85 671-673
• 123 Appelbaum P C, Bhamjee A, Scragg J N, Hallett A F, Bowen A J, Cooper R C. Streptococcus pneumoniae resistant to penicillin and chloramphenicol.  Lancet. 1977;  2 995-997
• 124 Koornhof H J, Wasas A, Klugman K. Antimicrobial resistance in Streptococcus pneumoniae: a South African perspective.  Clin Infect Dis. 1992;  15 84-94
• 125 Linares J, Garau J, Dominguez C, Perez J L. Antibiotic resistance and serotypes of Streptococcus pneumoniae from patients with community-acquired pneumococcal disease.  Antimicrob Agents Chemother. 1983;  23 545-547
• 126 Linares J, Pallares R, Alonso T et al.. Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitage Hospital, Barcelona, Spain (1979-1990).  Clin Infect Dis. 1992;  15 99-105
• 127 Fenoll A, Martin Bourgon C, Munoz R, Vicioso D, Casal J. Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing systemic infections in Spain, 1979-1989.  Rev Infect Dis. 1991;  13 56-60
• 128 Geslin P, Buu-Hoi A, Fremaux A, Acar J F. Antimicrobial resistance in Streptococcus pneumoniae: an epidemiological survey in France, 1970-1990.  Clin Infect Dis. 1992;  15 95-98
• 129 Dagan R, Yagupsky P, Goldbart A, Wasas A, Klugman K. Increasing prevalence of penicillin-resistant pneumococcal infections in children in southern Israel: implications for future immunization policies.  Pediatr Infect Dis J. 1994;  13 782-786
• 130 Marton A, Gulyas M, Munoz R, Tomasz A. Extremely high incidence of antibiotic resistance in clinical isolates of Streptococcus pneumoniae in Hungary.  J Infect Dis. 1991;  163 542-548
• 131 Marton A. Pneumococcal antimicrobial resistance: the problem in Hungary.  Clin Infect Dis. 1992;  15 106-111
• 132 Partial penicillin resistance (PPR) pneumococcal isolates recovered from Alaskan patients.  Alaska Med. 1987;  29 186-187
• 133 Bedos J P, Chevret S, Chastang C, Geslin P, Regnier B. Epidemiological features of and risk factors for infection by Streptococcus pneumoniae strains with diminished susceptibility to penicillin: findings of a French survey.  Clin Infect Dis. 1996;  22 63-72
• 134 Kam K M, Luey K Y, Fung S M, Yiu P P, Harden T J, Cheung M M. Emergence of multiple-antibiotic-resistant Streptococcus pneumoniae in Hong Kong.  Antimicrob Agents Chemother. 1995;  39 2667-2670
• 135 Doern G V, Brueggemann A, Holley Jr H P, Rauch A M. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study.  Antimicrob Agents Chemother. 1996;  40 1208-1213
• 136 Thornsberry C, Jones M E, Hickey M L, Mauriz Y, Kahn J, Sahm D F. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998.  J Antimicrob Chemother. 1999;  44 749-759
• 137 Schrag S J, McGee L, Whitney C G et al.. Emergence of Streptococcus pneumoniae with very-high-level resistance to penicillin.  Antimicrob Agents Chemother. 2004;  48 3016-3023
• 138 Zhanel G G, Palatnick L, Nichol K A, Bellyou T, Low D E, Hoban D J. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002.  Antimicrob Agents Chemother. 2003;  47 1867-1874
• 139 Pallares R, Capdevila O, Linares J et al.. The effect of cephalosporin resistance on mortality in adult patients with nonmeningeal systemic pneumococcal infections.  Am J Med. 2002;  113 120-126
• 139a Zhanel G G. Influence of pharmacokinetic and pharmacodynamic principles on antibiotic selection.  Curr Infect Dis Rep. 2001;  3 29-34
• 140 Barcus V A, Ghanekar K, Yeo M, Coffey T J, Dowson C G. Genetics of high level penicillin resistance in clinical isolates of Streptococcus pneumoniae .  FEMS Microbiol Lett. 1995;  126 299-303
• 141 Karlowsky J A, Jones M E, Draghi D C, Sahm D F. Clinical isolates of Streptococcus pneumoniae with different susceptibilities to ceftriaxone and cefotaxime.  Antimicrob Agents Chemother. 2003;  47 3155-3160
• 142 Smith A M, Klugman K P. Alterations in MurM, a cell wall muropeptide branching enzyme, increase high-level penicillin and cephalosporin resistance in Streptococcus pneumoniae .  Antimicrob Agents Chemother. 2001;  45 2393-2396
• 143 Chambers H F. Penicillin-binding protein-mediated resistance in pneumococci and staphylococci.  J Infect Dis. 1999;  179(Suppl 2) S353-S359
• 144 Munoz R, Dowson C G, Daniels M et al.. Genetics of resistance to third-generation cephalosporins in clinical isolates of Streptococcus pneumoniae .  Mol Microbiol. 1992;  6 2461-2465
• 145 Hakenbeck R, Konig A, Kern I et al.. Acquisition of five high-Mr penicillin-binding protein variants during transfer of high-level beta-lactam resistance from Streptococcus mitis to Streptococcus pneumoniae .  J Bacteriol. 1998;  180 1831-1840
• 146 Laible G, Spratt B G, Hakenbeck R. Interspecies recombinational events during the evolution of altered PBP 2x genes in penicillin-resistant clinical isolates of Streptococcus pneumoniae .  Mol Microbiol. 1991;  5 1993-2002
• 147 Reichmann P, Konig A, Marton A, Hakenbeck R. Penicillin-binding proteins as resistance determinants in clinical isolates of Streptococcus pneumoniae .  Microb Drug Resist. 1996;  2 177-181
• 148 Krauss J, Hakenbeck R. A mutation in the D,D-carboxypeptidase penicillin-binding protein 3 of Streptococcus pneumoniae contributes to cefotaxime resistance of the laboratory mutant C604.  Antimicrob Agents Chemother. 1997;  41 936-942
• 149 Smith A M, Klugman K P. Non-penicillin-binding protein mediated high-level penicillin and cephalosporin resistance in a Hungarian clone of Streptococcus pneumoniae .  Microb Drug Resist. 2000;  6 105-110
• 150 Doern G V, Pfaller M A, Kugler K, Freeman J, Jones R N. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program.  Clin Infect Dis. 1998;  27 764-770
• 151 Thornsberry C, Ogilvie P, Kahn J, Mauriz Y. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group.  Diagn Microbiol Infect Dis. 1997;  29 249-257
• 152 Brueggemann A B, Pfaller M A, Doern G V. Use of penicillin MICs to predict in vitro activity of other beta-lactam antimicrobial agents against Streptococcus pneumoniae .  J Clin Microbiol. 2001;  39 367-369
• 153 Hauser C, Aebi S, Muhlemann K. An internationally spread clone of Streptococcus pneumoniae evolves from low-level to higher-level penicillin resistance by uptake of penicillin-binding protein gene fragments from nonencapsulated pneumococci.  Antimicrob Agents Chemother. 2004;  48 3563-3566
• 154 Dowson C G, Johnson A P, Cercenado E, George R C. Genetics of oxacillin resistance in clinical isolates of Streptococcus pneumoniae that are oxacillin resistant and penicillin susceptible.  Antimicrob Agents Chemother. 1994;  38 49-53
• 155 Smith A M, Klugman K P. Site-specific mutagenesis analysis of PBP 1A from a penicillin-cephalosporin-resistant pneumococcal isolate.  Antimicrob Agents Chemother. 2003;  47 387-389
• 156 Nichol K A, Zhanel G G, Hoban D J. Penicillin-binding protein 1A, 2B, and 2X alterations in Canadian isolates of penicillin-resistant Streptococcus pneumoniae .  Antimicrob Agents Chemother. 2002;  46 3261-3264
• 157 du Plessis M, Bingen E, Klugman K P. Analysis of penicillin-binding protein genes of clinical isolates of Streptococcus pneumoniae with reduced susceptibility to amoxicillin.  Antimicrob Agents Chemother. 2002;  46 2349-2357
• 158 Perez-Trallero E, Marimon J M, Gonzalez A, Garcia-Rey C, Aguilar L. Genetic relatedness of recently collected Spanish respiratory tract Streptococcus pneumoniae isolates with reduced susceptibility to amoxicillin.  Antimicrob Agents Chemother. 2003;  47 3637-3639
• 159 Dagan R, Hoberman A, Johnson C et al.. Bacteriologic and clinical efficacy of high dose amoxicillin/clavulanate in children with acute otitis media.  Pediatr Infect Dis J. 2001;  20 829-837
• 160 Garau J, Twynholm M, Garcia-Mendez E, Siquier B, Rivero A. Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults.  J Antimicrob Chemother. 2003;  52 826-836
• 161 Berry V, Hoover J, Singley C, Woodnutt G. Comparative bacteriological efficacy of pharmacokinetically enhanced amoxicillin-clavulanate against Streptococcus pneumoniae with elevated amoxicillin MICs and Haemophilus influenzae .  Antimicrob Agents Chemother. 2005;  49 908-915
• 162 White A R, Kaye C, Poupard J, Pypstra R, Woodnutt G, Wynne B. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.  J Antimicrob Chemother. 2004;  53(Suppl 1) i3-20
• 163 McDougal L K, Rasheed J K, Biddle J W, Tenover F C. Identification of multiple clones of extended-spectrum cephalosporin-resistant Streptococcus pneumoniae isolates in the United States.  Antimicrob Agents Chemother. 1995;  39 2282-2288
• 164 Figueiredo A M, Connor J D, Severin A, Vaz Pato M V, Tomasz A. A pneumococcal clinical isolate with high-level resistance to cefotaxime and ceftriaxone.  Antimicrob Agents Chemother. 1992;  36 886-889
• 165 Smith A M, Klugman K P. Alterations in PBP 1A essential-for high-level penicillin resistance in Streptococcus pneumoniae .  Antimicrob Agents Chemother. 1998;  42 1329-1333
• 166 Waites K, Brown S. Antimicrobial resistance among isolates of respiratory tract infection pathogens from the southern United States: data from the PROTEKT US surveillance program 2000/2001.  South Med J. 2003;  96 974-985
• 167 Karlowsky J A, Thornsberry C, Critchley I A et al.. Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States.  Antimicrob Agents Chemother. 2003;  47 1790-1797
• 168 Sahm D F, Karlowsky J A, Kelly L J et al.. Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis.  Antimicrob Agents Chemother. 2001;  45 1037-1042
• 169 Powis J, McGeer A, Green K et al.. In vitro antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates obtained in Canada in 2002.  Antimicrob Agents Chemother. 2004;  48 3305-3311
• 170 Klugman K P, Capper T, Widdowson C A, Koornhof H J, Moser W. Increased activity of 16-membered lactone ring macrolides against erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae: characterization of South African isolates.  J Antimicrob Chemother. 1998;  42 729-734
• 171 Hofmann J, Cetron M S, Farley M M et al.. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta.  N Engl J Med. 1995;  333 481-486
• 172 Syrogiannopoulos G A, Grivea I N, Beratis N G et al.. Resistance patterns of Streptococcus pneumoniae from carriers attending day-care centers in southwestern Greece.  Clin Infect Dis. 1997;  25 188-194
• 173 Finkelstein J A, Huang S S, Daniel J et al.. Antibiotic-resistant Streptococcus pneumoniae in the heptavalent pneumococcal conjugate vaccine era: predictors of carriage in a multicommunity sample.  Pediatrics. 2003;  112 862-869
• 174 Craig A S, Erwin P C, Schaffner W et al.. Carriage of multidrug-resistant Streptococcus pneumoniae and impact of chemoprophylaxis during an outbreak of meningitis at a day care center.  Clin Infect Dis. 1999;  29 1257-1264
• 175 Nuorti J P, Butler J C, Crutcher J M et al.. An outbreak of multidrug-resistant pneumococcal pneumonia and bacteremia among unvaccinated nursing home residents.  N Engl J Med. 1998;  338 1861-1868
• 176 Crewe-Brown H H, Karstaedt A S, Saunders G L et al.. Streptococcus pneumoniae blood culture isolates from patients with and without human immunodeficiency virus infection: alterations in penicillin susceptibilities and in serogroups or serotypes.  Clin Infect Dis. 1997;  25 1165-1172
• 177 Mao C, Harper M, McIntosh K et al.. Invasive pneumococcal infections in human immunodeficiency virus-infected children.  J Infect Dis. 1996;  173 870-876
• 178 Meynard J L, Barbut F, Blum L et al.. Risk factors for isolation of Streptococcus pneumoniae with decreased susceptibility to penicillin G from patients infected with human immunodeficiency virus.  Clin Infect Dis. 1996;  22 437-440
• 179 Barnes D M, Whittier S, Gilligan P H, Soares S, Tomasz A, Henderson F W. Transmission of multidrug-resistant serotype 23F Streptococcus pneumoniae in group day care: evidence suggesting capsular transformation of the resistant strain in vivo.  J Infect Dis. 1995;  171 890-896
• 180 Hoge C W, Reichler M R, Dominguez E A et al.. An epidemic of pneumococcal disease in an overcrowded, inadequately ventilated jail.  N Engl J Med. 1994;  331 643-648
• 181 DeMaria Jr A, Browne K, Berk S L, Sherwood E J, McCabe W R. An outbreak of type 1 pneumococcal pneumonia in a men's shelter.  JAMA. 1980;  244 1446-1449
• 182 Dejsirilert S, Overweg K, Sluijter M et al.. Nasopharyngeal carriage of penicillin-resistant Streptococcus pneumoniae among children with acute respiratory tract infections in Thailand: a molecular epidemiological survey.  J Clin Microbiol. 1999;  37 1832-1838
• 183 Albanese B A, Roche J C, Pass M, Whitney C G, McEllistrem M C, Harrison L H. Geographic, demographic, and seasonal differences in penicillin-resistant Streptococcus pneumoniae in Baltimore.  Clin Infect Dis. 2002;  34 15-21
• 184 McEllistrem M C, Mendelsohn A B, Pass M et al.. Distribution of penicillin-nonsusceptible pneumococcal clones in the Baltimore metropolitan area and variables associated with drug resistance.  Clin Infect Dis. 2002;  34 704-707
• 185 Duchin J S, Breiman R F, Diamond A et al.. High prevalence of multidrug-resistant Streptococcus pneumoniae among children in a rural Kentucky community.  Pediatr Infect Dis J. 1995;  14 745-750
• 186 Ronchetti M P, Guglielmi F, Latini L et al.. Resistance patterns of Streptococcus pneumoniae from children in central Italy.  Eur J Clin Microbiol Infect Dis. 1999;  18 376-379
• 187 Kellner J D, Ford-Jones E L. Streptococcus pneumoniae carriage in children attending 59 Canadian child care centers. Toronto Child Care Centre Study Group.  Arch Pediatr Adolesc Med. 1999;  153 495-502
• 188 Mason Jr E O, Lamberth L B, Kershaw N L, Prosser B L, Zoe A, Ambrose P G. Streptococcus pneumoniae in the USA: in vitro susceptibility and pharmacodynamic analysis.  J Antimicrob Chemother. 2000;  45 623-631
• 189 Garcia-de-Lomas J, Gimeno C, Millas E et al.. Antimicrobial susceptibility of Streptococcus pneumoniae isolated from pediatric carriers in Spain.  Eur J Clin Microbiol Infect Dis. 1997;  16 11-13
• 190 Goldsmith C E, Moore J E, Murphy P G. Pneumococcal resistance in the UK.  J Antimicrob Chemother. 1997;  40(Suppl A) 11-8
• 191 Arrieta A, Arguedas A, Fernandez P et al.. High-dose azithromycin versus high-dose amoxicillin-clavulanate for treatment of children with recurrent or persistent acute otitis media.  Antimicrob Agents Chemother. 2003;  47 3179-3186
• 192 Moreno S, Garcia-Leoni M E, Cercenado E, Diaz M D, Bernaldo de Quiros J C, Bouza E. Infections caused by erythromycin-resistant Streptococcus pneumoniae: incidence, risk factors, and response to therapy in a prospective study.  Clin Infect Dis. 1995;  20 1195-1200
• 193 Hoban D J, Doern G V, Fluit A C, Roussel-Delvallez M, Jones R N. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999.  Clin Infect Dis. 2001;  32(Suppl 2) S81-S93
• 194 Farrell D J, Morrissey I, Bakker S, Buckridge S, Felmingham D. In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations.  Antimicrob Agents Chemother. 2004;  48 3169-3171
• 195 Brown S D, Farrell D J. Antibacterial susceptibility among Streptococcus pneumoniae isolated from paediatric and adult patients as part of the PROTEKT US study in 2001-2002.  J Antimicrob Chemother. 2004;  54(Suppl 1) i23-i29
• 196 Report MMWR . Resistance of Streptococcus pneumoniae to fluoroquinolones-United States, 1995-1999.  MMWR Morb Mortal Wkly Rep. 2001;  5 800-804
• 197 Felmingham D, Reinert R R, Hirakata Y, Rodloff A. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin.  J Antimicrob Chemother. 2002;  50(Suppl S1) 25-37
• 198 Hsueh P R, Teng L J, Wu T L et al.. Telithromycin- and fluoroquinolone-resistant Streptococcus pneumoniae in Taiwan with high prevalence of resistance to macrolides and beta-lactams: SMART program 2001 data.  Antimicrob Agents Chemother. 2003;  47 2145-2151
• 199 Perez-Trallero E, Fernandez-Mazarrasa C, Garcia-Rey C et al.. Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: results of a 1-year (1998-1999) multicenter surveillance study in Spain.  Antimicrob Agents Chemother. 2001;  45 3334-3340
• 200 Reinert R R, Lutticken R, Bryskier A, Al-Lahham A. Macrolide-resistant Streptococcus pneumoniae and Streptococcus pyogenes in the pediatric population in Germany during 2000-2001.  Antimicrob Agents Chemother. 2003;  47 489-493
• 201 Ho P, Yuen K, Yam W, Sai-yin Wong S, Luk W. Changing patterns of susceptibilities of blood, urinary and respiratory pathogens in Hong Kong.  J Hosp Infect. 1995;  31 305-317
• 202 Ho P L, Que T L, Tsang D N, Ng T K, Chow K H, Seto W H. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong.  Antimicrob Agents Chemother. 1999;  43 1310-1313
• 203 Kristinsson K G, Hjalmarsdottir M A, Steingrimsson O. Increasing penicillin resistance in pneumococci in Iceland.  Lancet. 1992;  339 1606-1607
• 204 Kristinsson K G. Epidemiology of penicillin resistant pneumococci in Iceland.  Microb Drug Resist. 1995;  1 121-125
• 205 Austin D J, Kristinsson K G, Anderson R M. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance.  Proc Natl Acad Sci U S A. 1999;  96 1152-1156
• 206 Castanheira M, Gales A C, Mendes R E, Jones R N, Sader H S. Antimicrobial susceptibility of Streptococcus pneumoniae in Latin America: results from five years of the SENTRY Antimicrobial Surveillance Program.  Clin Microbiol Infect. 2004;  10 645-651
• 207 Mendes C, Kiffer C R, Blosser-Middleton R S et al.. Antimicrobial susceptibility to levofloxacin and other antibacterial agents among common respiratory pathogens: a Brazilian perspective from the GLOBAL Surveillance Initiative 2001-2002.  Clin Microbiol Infect. 2004;  10 521-526
• 208 Kertesz D A, Di Fabio J L, de Cunto Brandileone M C et al.. Invasive Streptococcus pneumoniae infection in Latin American children: results of the Pan American Health Organization Surveillance Study.  Clin Infect Dis. 1998;  26 1355-1361
• 209 Prospective multicentre hospital surveillance of Streptococcus pneumoniae disease in India. Invasive Bacterial Infection Surveillance (IBIS) Group, International Clinical Epidemiology Network (INCLEN).  Lancet. 1999;  353 1216-1221
• 210 Saha S K, Rikitomi N, Ruhulamin M et al.. Antimicrobial resistance and serotype distribution of Streptococcus pneumoniae strains causing childhood infections in Bangladesh, 1993 to 1997.  J Clin Microbiol. 1999;  37 798-800
• 211 Huebner R E, Wasas A D, Klugman K P. Trends in antimicrobial resistance and serotype distribution of blood and cerebrospinal fluid isolates of Streptococcus pneumoniae in South Africa, 1991-1998.  Int J Infect Dis. 2000;  4 214-218
• 212 Joloba M L, Bajaksouzian S, Palavecino E, Whalen C, Jacobs M R. High prevalence of carriage of antibiotic-resistant Streptococcus pneumoniae in children in Kampala Uganda.  Int J Antimicrob Agents. 2001;  17 395-400
• 213 Ramdani-Bouguessa N, Rahal K. Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolated in Algiers, Algeria.  Antimicrob Agents Chemother. 2003;  47 824-826
• 214 Benbachir M, Benredjeb S, Boye C S et al.. Two-year surveillance of antibiotic resistance in Streptococcus pneumoniae in four African cities.  Antimicrob Agents Chemother. 2001;  45 627-629
• 215 Batt S L, Charalambous B M, Solomon A W et al.. Impact of azithromycin administration for trachoma control on the carriage of antibiotic-resistant Streptococcus pneumoniae .  Antimicrob Agents Chemother. 2003;  47 2765-2769
• 216 Spika J S, Facklam R R, Plikaytis B D, Oxtoby M J. Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979-1987. The Pneumococcal Surveillance Working Group.  J Infect Dis. 1991;  163 1273-1278
• 217 Jorgensen J H, Doern G V, Maher L A, Howell A W, Redding J S. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States.  Antimicrob Agents Chemother. 1990;  34 2075-2080
• 218 Breiman R F, Butler J C, Tenover F C, Elliott J A, Facklam R R. Emergence of drug-resistant pneumococcal infections in the United States.  JAMA. 1994;  271 1831-1835
• 219 Butler J C, Hofmann J, Cetron M S, Elliott J A, Facklam R R, Breiman R F. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System.  J Infect Dis. 1996;  174 986-993
• 220 Sahm D F, Jones M E, Hickey M L, Diakun D R, Mani S V, Thornsberry C. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe, 1997-1998.  J Antimicrob Chemother. 2000;  45 457-466
• 221 Jones M E, Staples A M, Critchley I et al.. Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States.  Antimicrob Agents Chemother. 2000;  44 2645-2652
• 222 Viladrich P F, Cabellos C, Pallares R et al.. High doses of cefotaxime in treatment of adult meningitis due to Streptococcus pneumoniae with decreased susceptibilities to broad-spectrum cephalosporins.  Antimicrob Agents Chemother. 1996;  40 218-220
• 223 Ortega M, Marco F, Soriano A, Garcia E, Martinez J A, Mensa J. Lack of vancomycin tolerance in Streptococcus pneumoniae strains isolated in Barcelona, Spain, from 1999 to 2001.  Antimicrob Agents Chemother. 2003;  47 1976-1978
• 224 Friedland I R, Klugman K P. Antibiotic-resistant pneumococcal disease in South African children.  Am J Dis Child. 1992;  146 920-923
• 225 Johnson A P, Livermore D M, Woodford N, Quoraishi A, Freeman R. High-level beta-lactam resistance in strains of Streptococcus pneumoniae isolated in the UK.  J Antimicrob Chemother. 1998;  42 115-116
• 226 John C C. Treatment failure with use of a third-generation cephalosporin for penicillin-resistant pneumococcal meningitis: case report and review.  Clin Infect Dis. 1994;  18 188-193
• 227 Ahronheim G A, Reich B, Marks M I. Penicillin-insensitive pneumococci: case report and review.  Am J Dis Child. 1979;  133 187-191
• 228 Howes V J, Mitchell R G. Meningitis due to relatively penicillin-resistant pneumococcus.  BMJ. 1976;  1 996
• 229 Friedland I R, Klugman K P. Failure of chloramphenicol therapy in penicillin-resistant pneumococcal meningitis.  Lancet. 1992;  339 405-408
• 230 Dagan R, Abramson O, Leibovitz E et al.. Impaired bacteriologic response to oral cephalosporins in acute otitis media caused by pneumococci with intermediate resistance to penicillin.  Pediatr Infect Dis J. 1996;  15 980-985
• 231 Dagan R, Leibovitz E, Leiberman A, Yagupsky P. Clinical significance of antibiotic resistance in acute otitis media and implication of antibiotic treatment on carriage and spread of resistant organisms.  Pediatr Infect Dis J. 2000;  19(5 Suppl) S57-S65
• 232 Dowell S F, Butler J C, Giebink G S et al.. Acute otitis media: management and surveillance in an era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group.  Pediatr Infect Dis J. 1999;  18 1-9
• 233 Kaplan S L, Mason Jr E O, Barson W J et al.. Outcome of invasive infections outside the central nervous system caused by Streptococcus pneumoniae isolates nonsusceptible to ceftriazone in children treated with beta-lactam antibiotics.  Pediatr Infect Dis J. 2001;  20 392-396
• 234 Therapy for children with invasive pneumococcal infections. American Academy of Pediatrics Committee on Infectious Diseases.  Pediatrics. 1997;  99 289-299
• 235 Leggiadro R J. The clinical impact of resistance in the management of pneumococcal disease.  Infect Dis Clin North Am. 1997;  11 867-874
• 236 Paris M M, Ramilo O, McCracken Jr G H. Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae .  Antimicrob Agents Chemother. 1995;  39 2171-2175
• 237 Arditi M, Mason Jr E O, Bradley J S et al.. Three-year multicenter surveillance of pneumococcal meningitis in children: clinical characteristics, and outcome related to penicillin susceptibility and dexamethasone use.  Pediatrics. 1998;  102 1087-1097
• 238 Fiore A E, Moroney J F, Farley M M et al.. Clinical outcomes of meningitis caused by Streptococcus pneumoniae in the era of antibiotic resistance.  Clin Infect Dis. 2000;  30 71-77
• 239 Auburtin M, Porcher R, Bruneel F et al.. Pneumococcal meningitis in the intensive care unit: prognostic factors of clinical outcome in a series of 80 cases.  Am J Respir Crit Care Med. 2002;  165 713-717
• 240 Tan T Q, Schutze G E, Mason Jr E O, Kaplan S L. Antibiotic therapy and acute outcome of meningitis due to Streptococcus pneumoniae considered intermediately susceptible to broad-spectrum cephalosporins.  Antimicrob Agents Chemother. 1994;  38 918-923
• 241 Frankel R E, Virata M, Hardalo C, Altice F L, Friedland G. Invasive pneumococcal disease: clinical features, serotypes, and antimicrobial resistance patterns in cases involving patients with and without human immunodeficiency virus infection.  Clin Infect Dis. 1996;  23 577-584
• 242 Kalin M, Ortqvist A, Almela M et al.. Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in five countries.  J Infect Dis. 2000;  182 840-847
• 243 Marfin A A, Sporrer J, Moore P S, Siefkin A D. Risk factors for adverse outcome in persons with pneumococcal pneumonia.  Chest. 1995;  107 457-462
• 244 Watanakunakorn C, Greifenstein A, Stroh K et al.. Pneumococcal bacteremia in three community teaching hospitals from 1980 to 1989.  Chest. 1993;  103 1152-1156
• 245 Afessa B, Greaves W L, Frederick W R. Pneumococcal bacteremia in adults: a 14-year experience in an inner-city university hospital.  Clin Infect Dis. 1995;  21 345-351
• 246 Castillo E M, Rickman L S, Brodine S K, Ledbetter E K, Kelly C. Streptococcus pneumoniae: bacteremia in an era of penicillin resistance.  Am J Infect Control. 2000;  28 239-243
• 247 Moroney J F, Fiore A E, Harrison L H et al.. Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance.  Clin Infect Dis. 2001;  33 797-805
• 248 Roson B, Carratala J, Tubau F et al.. Usefulness of beta-lactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone.  Microb Drug Resist. 2001;  7 85-96
• 249 Wu T T, Hsueh P R, Lee L N, Yang P C, Luh K T. Pneumonia caused by penicillin-nonsusceptible Streptococcus pneumoniae: clinical characteristics, prognostic factors, and outcomes.  J Formos Med Assoc. 2000;  99 18-23
• 250 Bradley J S, Connor J D. Ceftriaxone failure in meningitis caused by Streptococcus pneumoniae with reduced susceptibility to beta-lactam antibiotics.  Pediatr Infect Dis J. 1991;  10 871-873
• 251 Viladrich P F, Gudiol F, Linares J, Rufi G, Ariza J, Pallares R. Characteristics and antibiotic therapy of adult meningitis due to penicillin-resistant pneumococci.  Am J Med. 1988;  84 839-846
• 252 Friedland I R, Shelton S, Paris M et al.. Dilemmas in diagnosis and management of cephalosporin-resistant Streptococcus pneumoniae meningitis.  Pediatr Infect Dis J. 1993;  12 196-200
• 253 Guibert M, Chahime H, Petit J, Odievre M, Labrune P. Failure of cefotaxime treatment in two children with meningitis caused by highly penicillin-resistant Streptococcus pneumoniae .  Acta Paediatr. 1995;  84 831-833
• 254 Greene G S, Demasi R. Case report: penicillin-resistant pneumococcal meningitis: navigating a therapeutic minefield.  Am J Med Sci. 1996;  311 180-185
• 255 Pacheco T R, Cooper C K, Hardy D J, Betts R F, Bonnez W. Failure of cefotaxime treatment in an adult with Streptococcus pneumoniae meningitis.  Am J Med. 1997;  102 303-305
• 256 Sacho H, Klugman K P, Koornhof H J, Ruff P. Community-acquired pneumonia in an adult due to a multiply-resistant pneumococcus.  J Infect. 1987;  14 188-189
• 257 Buckingham S C, Brown S P, Joaquin V H. Breakthrough bacteremia and meningitis during treatment with cephalosporins parenterally for pneumococcal pneumonia.  J Pediatr. 1998;  132 174-176
• 258 Dowell S F, Smith T, Leversedge K, Snitzer J. Failure of treatment of pneumonia associated with highly resistant pneumococci in a child.  Clin Infect Dis. 1999;  29 462-463
• 259 Silverstein M, Bachur R, Harper M B. Clinical implications of penicillin and ceftriaxone resistance among children with pneumococcal bacteremia.  Pediatr Infect Dis J. 1999;  18 35-41
• 260 Klugman K P, Lonks J R. Hidden epidemic of macrolide-resistant pneumococci.  Emerg Infect Dis. 2005;  11 802-807
• 261 Verhaegen J, Glupczynski Y, Verbist L et al.. Capsular types and antibiotic susceptibility of pneumococci isolated from patients in Belgium with serious infections, 1980-1993.  Clin Infect Dis. 1995;  20 1339-1345
• 262 Wierzbowski A K, Swedlo D, Boyd D et al.. Molecular epidemiology and prevalence of macrolide efflux genes mef(A) and mef(E) in Streptococcus pneumoniae obtained in Canada from 1997 to 2002.  Antimicrob Agents Chemother. 2005;  49 1257-1261
• 263 Jorgensen J H, Swenson J M, Tenover F C et al.. Development of interpretive criteria and quality control limits for macrolide and clindamycin susceptibility testing of Streptococcus pneumoniae .  J Clin Microbiol. 1996;  34 2679-2684
• 264 Vester B, Douthwaite S. Macrolide resistance conferred by base substitutions in 23S rRNA.  Antimicrob Agents Chemother. 2001;  45 1-12
• 265 Jalava J, Kataja J, Seppala H, Huovinen P. In vitro activities of the novel ketolide telithromycin (HMR 3647) against erythromycin-resistant Streptococcus species.  Antimicrob Agents Chemother. 2001;  45 789-793
• 266 Zhanel G G, Dueck M, Hoban D J et al.. Review of macrolides and ketolides: focus on respiratory tract infections.  Drugs. 2001;  61 443-498
• 267 Edelstein P H. Pneumococcal resistance to macrolides, lincosamides, ketolides, and streptogramin B agents: molecular mechanisms and resistance phenotypes.  Clin Infect Dis. 2004;  38(Suppl 4) S322-S327
• 268 Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications.  Clin Infect Dis. 2002;  34 482-492
• 269 Tait-Kamradt A, Davies T, Appelbaum P C et al.. Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from eastern Europe and North America.  Antimicrob Agents Chemother. 2000;  44 3395-3401
• 270 Canu A, Malbruny B, Coquemont M, Davies T A, Appelbaum P C, Leclercq R. Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae .  Antimicrob Agents Chemother. 2002;  46 125-131
• 271 Oster P, Zanchi A, Cresti S et al.. Patterns of macrolide resistance determinants among community-acquired Streptococcus pneumoniae isolates over a 5-year period of decreased macrolide susceptibility rates.  Antimicrob Agents Chemother. 1999;  43 2510-2512
• 272 Syrogiannopoulos G A, Grivea I N, Tait-Kamradt A et al.. Identification of an erm(A) erythromycin resistance methylase gene in Streptococcus pneumoniae isolated in Greece.  Antimicrob Agents Chemother. 2001;  45 342-344
• 273 Syrogiannopoulos G A, Grivea I N, Ednie L M et al.. Antimicrobial susceptibility and macrolide resistance inducibility of Streptococcus pneumoniae carrying erm(A), erm(B), or mef(A).  Antimicrob Agents Chemother. 2003;  47 2699-2702
• 274 Montanari M P, Mingoia M, Giovanetti E, Varaldo P E. Differentiation of resistance phenotypes among erythromycin-resistant pneumococci.  J Clin Microbiol. 2001;  39 1311-1315
• 275 Rosato A, Vicarini H, Leclercq R. Inducible or constitutive expression of resistance in clinical isolates of streptococci and enterococci cross-resistant to erythromycin and lincomycin.  J Antimicrob Chemother. 1999;  43 559-562
• 276 Cerda Zolezzi P, Laplana L M, Calvo C R, Cepero P G, Erazo M C, Gomez-Lus R. Molecular basis of resistance to macrolides and other antibiotics in commensal viridans group streptococci and Gemella spp. and transfer of resistance genes to Streptococcus pneumoniae .  Antimicrob Agents Chemother. 2004;  48 3462-3467
• 277 Gay K, Stephens D S. Structure and dissemination of a chromosomal insertion element encoding macrolide efflux in Streptococcus pneumoniae .  J Infect Dis. 2001;  184 56-65
• 278 Kataja J, Huovinen P, Skurnik M, Seppala H. Erythromycin resistance genes in group A streptococci in Finland. The Finnish Study Group for Antimicrobial Resistance.  Antimicrob Agents Chemother. 1999;  43 48-52
• 279 Del Grosso M, Scotto d'Abusco A, Iannelli F, Pozzi G, Pantosti A. Tn2009, a Tn916-like element containing mef(E) in Streptococcus pneumoniae .  Antimicrob Agents Chemother. 2004;  48 2037-2042
• 280 Santagati M, Iannelli F, Oggioni M R, Stefani S, Pozzi G. Characterization of a genetic element carrying the macrolide efflux gene mef(A) in Streptococcus pneumoniae .  Antimicrob Agents Chemother. 2000;  44 2585-2587
• 281 Del Grosso M, Iannelli F, Messina C et al.. Macrolide efflux genes mef(A) and mef(E) are carried by different genetic elements in Streptococcus pneumoniae .  J Clin Microbiol. 2002;  40 774-778
• 282 Farrell D J, Jenkins S G. Distribution across the USA of macrolide resistance and macrolide resistance mechanisms among Streptococcus pneumoniae isolates collected from patients with respiratory tract infections: PROTEKT US 2001-2002.  J Antimicrob Chemother. 2004;  54(Suppl 1) i17-i22
• 283 Amezaga M R, Carter P E, Cash P, McKenzie H. Molecular epidemiology of erythromycin resistance in Streptococcus pneumoniae isolates from blood and noninvasive sites.  J Clin Microbiol. 2002;  40 3313-3318
• 284 Montanari M P, Mingoia M, Cochetti I, Varaldo P E. Phenotypes and genotypes of erythromycin-resistant pneumococci in Italy.  J Clin Microbiol. 2003;  41 428-431
• 285 Johnston N J, De Azavedo J C, Kellner J D, Low D E. Prevalence and characterization of the mechanisms of macrolide, lincosamide, and streptogramin resistance in isolates of Streptococcus pneumoniae .  Antimicrob Agents Chemother. 1998;  42 2425-2426
• 286 McDougal L K, Tenover F C, Lee L N et al.. Detection of Tn917-like sequences within a Tn916-like conjugative transposon (Tn3872) in erythromycin-resistant isolates of Streptococcus pneumoniae .  Antimicrob Agents Chemother. 1998;  42 2312-2318
• 287 Siegel R E. The significance of serum vs tissue levels of antibiotics in the treatment of penicillin-resistant Streptococcus pneumoniae and community-acquired pneumonia: are we looking in the wrong place?.  Chest. 1999;  116 535-538
• 288 Shortridge V D, Doern G V, Brueggemann A B, Beyer J M, Flamm R K. Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995.  Clin Infect Dis. 1999;  29 1186-1188
• 289 Schmitz F J, Perdikouli M, Beeck A, Verhoef J, Fluit A C. Molecular surveillance of macrolide, tetracycline and quinolone resistance mechanisms in 1191 clinical European Streptococcus pneumoniae isolates.  Int J Antimicrob Agents. 2001;  18 433-436
• 290 Farrell D J, Douthwaite S, Morrissey I et al.. Macrolide resistance by ribosomal mutation in clinical isolates of Streptococcus pneumoniae from the PROTEKT 1999-2000 study.  Antimicrob Agents Chemother. 2003;  47 1777-1783
• 291 Baquero F, Garcia-Rodriguez J A, Garcia de Lomas J, Aguilar L. Antimicrobial resistance of 1,113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: results of a 1-year (1996-1997) multicenter surveillance study. The Spanish Surveillance Group for Respiratory Pathogens.  Antimicrob Agents Chemother. 1999;  43 357-359
• 292 Morosini M I, Loza E, del Campo R, Almaraz F, Baquero F, Canton R. Fluoroquinolone-resistant Streptococcus pneumoniae in Spain: activities of garenoxacin against clinical isolates including strains with altered topoisomerases.  Antimicrob Agents Chemother. 2003;  47 2692-2695
• 293 Bingen E, Doit C, Loukil C et al.. Activity of telithromycin against penicillin-resistant Streptococcus pneumoniae isolates recovered from French children with invasive and noninvasive infections.  Antimicrob Agents Chemother. 2003;  47 2345-2347
• 294 Tiemei Z, Xiangqun F, Youning L. Resistance phenotypes and genotypes of erythromycin-resistant Streptococcus pneumoniae isolates in Beijing and Shenyang, China.  Antimicrob Agents Chemother. 2004;  48 4040-4041
• 295 Zhanel G G, Karlowsky J A, Palatnick L, Vercaigne L, Low D E, Hoban D J. Prevalence of antimicrobial resistance in respiratory tract isolates of Streptococcus pneumoniae: results of a Canadian national surveillance study. The Canadian Respiratory Infection Study Group.  Antimicrob Agents Chemother. 1999;  43 2504-2509
• 296 Jones M E, Sahm D F, Martin N et al.. Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory season.  Antimicrob Agents Chemother. 2000;  44 462-466
• 297 Pihlajamaki M, Jalava J, Huovinen P, Kotilainen P. Antimicrobial resistance of invasive pneumococci in Finland in 1999-2000.  Antimicrob Agents Chemother. 2003;  47 1832-1835
• 298 Reinert R R, Al-Lahham A, Lemperle M et al.. Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany.  J Antimicrob Chemother. 2002;  49 61-68
• 299 Nishijima T, Saito Y, Aoki A, Toriya M, Toyonaga Y, Fujii R. Distribution of mefE and ermB genes in macrolide-resistant strains of Streptococcus pneumoniae and their variable susceptibility to various antibiotics.  J Antimicrob Chemother. 1999;  43 637-643
• 300 Tait-Kamradt A, Davies T, Cronan M, Jacobs M R, Appelbaum P C, Sutcliffe J. Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage.  Antimicrob Agents Chemother. 2000;  44 2118-2125
• 301 Pihlajamaki M, Kataja J, Seppala H et al.. Ribosomal mutations in Streptococcus pneumoniae clinical isolates.  Antimicrob Agents Chemother. 2002;  46 654-658
• 302 Jacobsen B L, Skou M, Hammerum A M, Jensen L B. Horizontal transfer of the satA gene encoding streptogramin A resistance between isogenic Enterococcus faecium strains in the gastrointestinal tract of gnotobiotic rats.  Microb Ecol Health Dis. 1999;  11 241-247
• 303 Felmingham D, Washington J. Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens: findings of the Alexander Project 1992-1996.  J Chemother. 1999;  11(Suppl 1) 5-21
• 304 Dias R, Canica M. Emergence of invasive erythromycin-resistant Streptococcus pneumoniae strains in Portugal: contribution and phylogenetic relatedness of serotype 14.  J Antimicrob Chemother. 2004;  54 1035-1039
• 305 Hamilton-Miller J M, Shah S. Comparative in-vitro activity of ketolide HMR 3647 and four macrolides against gram-positive cocci of known erythromycin susceptibility status.  J Antimicrob Chemother. 1998;  41 649-653
• 306 Sweeney M T, Zurenko G E. In vitro activities of linezolid combined with other antimicrobial agents against staphylococci, enterococci, pneumococci, and selected gram-negative organisms.  Antimicrob Agents Chemother. 2003;  47 1902-1906
• 307 Anderegg T R, Sader H S, Fritsche T R, Ross J E, Jones R N. Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program.  Int J Antimicrob Agents. 2005;  26 13-21
• 308 Diekema D J, Pfaller M A, Jones R N et al.. Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in the USA, Canada and Latin America. SENTRY Participants Group.  Int J Antimicrob Agents. 2000;  13 257-271
• 309 Melander E, Molstad S, Persson K, Hansson H B, Soderstrom M, Ekdahl K. Previous antibiotic consumption and other risk factors for carriage of penicillin-resistant Streptococcus pneumoniae in children.  Eur J Clin Microbiol Infect Dis. 1998;  17 834-838
• 310 Block S L, Harrison C J, Hedrick J A et al.. Penicillin-resistant Streptococcus pneumoniae in acute otitis media: risk factors, susceptibility patterns and antimicrobial management.  Pediatr Infect Dis J. 1995;  14 751-759
• 311 Principi N, Marchisio P, Schito G C, Mannelli S. Risk factors for carriage of respiratory pathogens in the nasopharynx of healthy children. Ascanius Project Collaborative Group.  Pediatr Infect Dis J. 1999;  18 517-523
• 312 Doern G V, Brown S D. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01.  J Infect. 2004;  48 56-65
• 313 Reinert R R, Queck A, Kaufhold A, Kresken M, Lutticken R. Antimicrobial resistance and type distribution of Streptococcus pneumoniae isolates causing systemic infections in Germany, 1992-1994.  Clin Infect Dis. 1995;  21 1398-1401
• 314 Richard M P, Aguado A G, Mattina R, Marre R. Sensitivity to sparfloxacin and other antibiotics, of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis strains isolated from adult patients with community-acquired lower respiratory tract infections: a European multicentre study. SPAR Study Group. Surveillance Programme of Antibiotic Resistance.  J Antimicrob Chemother. 1998;  41 207-214
• 315 Marchese A, Debbia E, Pesce A, Schito G C. Comparative activities of amoxycillin and 10 other oral drugs against penicillin-susceptible and -resistant Streptococcus pneumoniae strains recently isolated in Italy.  Clin Microbiol Infect. 1998;  4 170-172
• 316 Schito G C, Debbia E A, Marchese A. The evolving threat of antibiotic resistance in Europe: new data from the Alexander Project.  J Antimicrob Chemother. 2000;  46(Suppl T1) 3-9
• 317 Arpin C, Canron M H, Noury P, Quentin C. Emergence of mefA and mefE genes in beta-haemolytic streptococci and pneumococci in France.  J Antimicrob Chemother. 1999;  44 133-134
• 318 Kanavaki S, Karabela S, Marinis E, Legakis N J. Antibiotic resistance of clinical isolates of Streptococcus pneumoniae in Greece.  J Clin Microbiol. 1994;  32 3056-3058
• 319 Ednie L M, Visalli M A, Jacobs M R, Appelbaum P C. Comparative activities of clarithromycin, erythromycin, and azithromycin against penicillin-susceptible and penicillin-resistant pneumococci.  Antimicrob Agents Chemother. 1996;  40 1950-1952
• 320 Friedland I R, McCracken Jr G H. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae .  N Engl J Med. 1994;  331 377-382
• 321 Bergan T, Gaustad P, Hoiby E A et al.. Antibiotic resistance of pneumococci in Norway.  Int J Antimicrob Agents. 1998;  10 77-81
• 322 Manninen R, Huovinen P, Nissinen A. Increasing antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in Finland.  J Antimicrob Chemother. 1997;  40 387-392
• 323 Nissinen A, Leinonen M, Huovinen P et al.. Antimicrobial resistance of Streptococcus pneumoniae in Finland, 1987-1990.  Clin Infect Dis. 1995;  20 1275-1280
• 324 Berner R. Antimicrobial susceptibility patterns of Streptococcus pneumoniae and Haemophilus influenzae in a German pediatric hospital, 1993 to 1997.  Pediatr Infect Dis J. 1998;  17 925-927
• 325 Mittermayer H, Jebelean C, Binder L, Haditsch M, Watschinger R. Antibiotic susceptibility of pneumococci isolated in Austria over a four-year period.  Eur J Clin Microbiol Infect Dis. 1996;  15 817-820
• 326 Boswell T C, Frodsham D, Nye K J, Smith E G. Antibiotic resistance and serotypes of Streptococcus pneumoniae at Birmingham Public Health Laboratory, 1989-94.  J Infect. 1996;  33 17-22
• 327 Aszkenasy O M, George R C, Begg N T. Pneumococcal bacteraemia and meningitis in England and Wales 1982 to 1992.  Commun Dis Rep CDR Rev. 1995;  5 R45-R50
• 328 Dagan R, Melamed R, Muallem M, Piglansky L, Yagupsky P. Nasopharyngeal colonization in southern Israel with antibiotic-resistant pneumococci during the first 2 years of life: relation to serotypes likely to be included in pneumococcal conjugate vaccines.  J Infect Dis. 1996;  174 1352-1355
• 329 Barry A L, Pfaller M A, Fuchs P C, Packer R R. In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. Medical Centers in 1992 and 1993.  Antimicrob Agents Chemother. 1994;  38 2419-2425
• 330 Mason Jr E O, Lamberth L B, Wald E R, Bradley J S, Barson W J, Kaplan S L. In vitro activities of cethromycin (ABT-773), a new ketolide, against Streptococcus pneumoniae strains that are not susceptible to penicillin or macrolides.  Antimicrob Agents Chemother. 2003;  47 166-169
• 331 Karchmer A W. Increased antibiotic resistance in respiratory tract pathogens: PROTEKT US-an update.  Clin Infect Dis. 2004;  39 S139-S50
• 332 Louie M, Louie L, Papia G, Talbot J, Lovgren M, Simor A E. Molecular analysis of the genetic variation among penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae serotypes in Canada.  J Infect Dis. 1999;  179 892-900
• 333 Davies T, Goering R V, Lovgren M, Talbot J A, Jacobs M R, Appelbaum P C. Molecular epidemiological survey of penicillin-resistant Streptococcus pneumoniae from Asia, Europe, and North America.  Diagn Microbiol Infect Dis. 1999;  34 7-12
• 334 Givon-Lavi N, Dagan R, Fraser D, Yagupsky P, Porat N. Marked differences in pneumococcal carriage and resistance patterns between day care centers located within a small area.  Clin Infect Dis. 1999;  29 1274-1280
• 335 Millar M R, Brown N M, Tobin G W, Murphy P J, Windsor A C, Speller D C. Outbreak of infection with penicillin-resistant Streptococcus pneumoniae in a hospital for the elderly.  J Hosp Infect. 1994;  27 99-104
• 336 Quick R E, Hoge C W, Hamilton D J, Whitney C J, Borges M, Kobayashi J M. Underutilization of pneumococcal vaccine in nursing home in Washington State: report of a serotype-specific outbreak and a survey.  Am J Med. 1993;  94 149-152
• 337 Mercat A, Nguyen J, Dautzenberg B. An outbreak of pneumococcal pneumonia in two men's shelters.  Chest. 1991;  99 147-151
• 338 Morita J Y, Kahn E, Thompson T et al.. Impact of azithromycin on oropharyngeal carriage of group A Streptococcus and nasopharyngeal carriage of macrolide-resistant Streptococcus pneumoniae .  Pediatr Infect Dis J. 2000;  19 41-46
• 339 Leach A J, Shelby-James T M, Mayo M et al.. A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae .  Clin Infect Dis. 1997;  24 356-362
• 340 Chern K C, Shrestha S K, Cevallos V et al.. Alterations in the conjunctival bacterial flora following a single dose of azithromycin in a trachoma endemic area.  Br J Ophthalmol. 1999;  83 1332-1335
• 341 McGee L, Klugman K P, Wasas A, Capper T, Brink A. Serotype 19f multiresistant pneumococcal clone harboring two erythromycin resistance determinants (erm(B) and mef(A)) in South Africa.  Antimicrob Agents Chemother. 2001;  45 1595-1598
• 342 McGee L, Wang H, Wasas A, Huebner R, Chen M, Klugman K P. Prevalence of serotypes and molecular epidemiology of Streptococcus pneumoniae strains isolated from children in Beijing, China: identification of two novel multiply-resistant clones.  Microb Drug Resist. 2001;  7 55-63
• 343 Ko K S, Song J H. Evolution of erythromycin-resistant Streptococcus pneumoniae from Asian countries that contains erm(B) and mef(A) genes.  J Infect Dis. 2004;  190 739-747
• 344 Waites K B, Jones K E, Kim K H et al.. Dissemination of macrolide-resistant Streptococcus pneumoniae isolates containing both erm(B) and mef(A) in South Korea.  J Clin Microbiol. 2003;  41 5787-5791
• 345 Farrell D J, Morrissey I, Bakker S, Morris L, Buckridge S, Felmingham D. Molecular epidemiology of multiresistant Streptococcus pneumoniae with both erm(B)- and mef(A)-mediated macrolide resistance.  J Clin Microbiol. 2004;  42 764-768
• 346 Bean D C, Klena J D. Prevalence of erm(A) and mef(B) erythromycin resistance determinants in isolates of Streptococcus pneumoniae from New Zealand.  J Antimicrob Chemother. 2002;  50 597-599
• 347 Weiss K, Guilbault C, Cortes L, Restieri C, Low D E. Genotypic characterization of macrolide-resistant strains of Streptococcus pneumoniae isolated in Quebec, Canada, and in vitro activity of ABT-773 and telithromycin.  J Antimicrob Chemother. 2002;  50 403-406
• 348 Varaldo P E, Debbia E A, Nicoletti G et al.. Nationwide survey in Italy of treatment of Streptococcus pyogenes pharyngitis in children: influence of macrolide resistance on clinical and microbiological outcomes. Artemis-Italy Study Group.  Clin Infect Dis. 1999;  29 869-873
• 349 Gleason P P, Meehan T P, Fine J M, Galusha D H, Fine M J. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia.  Arch Intern Med. 1999;  159 2562-2572
• 350 Dudas V, Hopefl A, Jacobs R, Guglielmo B J. Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of nonteaching US community hospitals.  Ann Pharmacother. 2000;  34 446-452
• 351 Gilbert K, Gleason P P, Singer D E et al.. Variations in antimicrobial use and cost in more than 2,000 patients with community-acquired pneumonia.  Am J Med. 1998;  104 17-27
• 352 Plouffe J, Schwartz D B, Kolokathis A et al.. Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. The Azithromycin Intravenous Clinical Trials Group.  Antimicrob Agents Chemother. 2000;  44 1796-1802
• 353 McCarty J M. Clarithromycin in the management of community-acquired pneumonia.  Clin Ther. 2000;  22 281-294 , discussion 65
• 354 Lode H, Garau J, Grassi C et al.. Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin.  Eur Respir J. 1995;  8 1999-2007
• 355 Genne D, Siegrist H H, Humair L, Janin-Jaquat B, de Torrente A. Clarithromycin versus amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia.  Eur J Clin Microbiol Infect Dis. 1997;  16 783-788
• 356 Kinasewitz G, Wood R G. Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia.  Eur J Clin Microbiol Infect Dis. 1991;  10 872-877
• 357 Reid Jr R, Bradley J S, Hindler J. Pneumococcal meningitis during therapy of otitis media with clarithromycin.  Pediatr Infect Dis J. 1995;  14 1104-1105
• 358 Jackson M A, Burry V F, Olson L C, Duthie S E, Kearns G L. Breakthrough sepsis in macrolide-resistant pneumococcal infection.  Pediatr Infect Dis J. 1996;  15 1049-1051
• 359 Zapalac J S, Billings K R, Schwade N D, Roland P S. Suppurative complications of acute otitis media in the era of antibiotic resistance.  Arch Otolaryngol Head Neck Surg. 2002;  128 660-663
• 360 Musher D M, Dowell M E, Shortridge V D et al.. Emergence of macrolide resistance during treatment of pneumococcal pneumonia.  N Engl J Med. 2002;  346 630-631
• 361 Van Kerkhoven D, Peetermans W E, Verbist L, Verhaegen J. Breakthrough pneumococcal bacteraemia in patients treated with clarithromycin or oral beta-lactams.  J Antimicrob Chemother. 2003;  51 691-696
• 362 Rzeszutek M, Wierzbowski A, Hoban D J, Conly J, Bishai W, Zhanel G G. A review of clinical failures associated with macrolide-resistant Streptococcus pneumoniae .  Int J Antimicrob Agents. 2004;  24 95-104
• 363 Martinez J A, Horcajada J P, Almela M et al.. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia.  Clin Infect Dis. 2003;  36 389-395
• 364 Waterer G W, Somes G W, Wunderink R G. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia.  Arch Intern Med. 2001;  161 1837-1842
• 365 Rothermel C D. Penicillin and macrolide resistance in pneumococcal pneumonia: does in vitro resistance affect clinical outcomes?.  Clin Infect Dis. 2004;  38(Suppl 4) S346-S349
• 366 Bishai W. A testament to sustained macrolide efficacy.  Clin Infect Dis. 2003;  36 935-936 , author reply 6-7
• 367 Craig W A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.  Clin Infect Dis. 1998;  26 1-10 , quiz 1-2
• 368 Amsden G W. Pneumococcal macrolide resistance: myth or reality?.  J Antimicrob Chemother. 1999;  44 1-6
• 369 Jacobs M R. In vivo veritas: in vitro macrolide resistance in systemic Streptococcus pneumoniae infections does result in clinical failure.  Clin Infect Dis. 2002;  35 565-569
• 370 Rodvold K A, Gotfried M H, Danziger L H, Servi R J. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers.  Antimicrob Agents Chemother. 1997;  41 1399-1402
• 371 Rapp R P. Pharmacokinetics and pharmacodynamics of intravenous and oral azithromycin: enhanced tissue activity and minimal drug interactions.  Ann Pharmacother. 1998;  32 785-793
• 372 Tamaoki J, Takeyama K, Tagaya E, Konno K. Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections.  Antimicrob Agents Chemother. 1995;  39 1688-1690
• 373 File Jr T M, Segreti J, Dunbar L et al.. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.  Antimicrob Agents Chemother. 1997;  41 1965-1972
• 374 Zhanel G G, DeCorby M, Noreddin A et al.. Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations.  J Antimicrob Chemother. 2003;  52 83-88
• 374a Noreddin A M, Roberts D, Nichol K, Wierzbowski A, Hoban D J, Zhanel G G. Pharmacodynamic modeling of clarithromycin against macrolide-resistant [PCR-positive mefA or ermB] Streptococcus pneumoniae simulating clinically achievable serum and epithelial lining fluid free drug concentrations.  Antimicrob Agents Chemother. 2002;  46 4029-4034
• 375 Zhanel G G, Johanson C, Laing N, Hisanaga T, Wierzbowski A, Hoban D J. Pharmacodynamic activity of telithromycin at simulated clinically achievable free-drug concentrations in serum and epithelial lining fluid against efflux (mefE)-producing macrolide-resistant Streptococcus pneumoniae for which telithromycin MICs vary.  Antimicrob Agents Chemother. 2005;  49 1943-1948
• 376 Lonks J R, Goldmann D A. Telithromycin: a ketolide antibiotic for treatment of respiratory tract infections.  Clin Infect Dis. 2005;  40 1657-1664
• 377 Davis R E, Knappenberger P C, Novicoff W M, Michaels P J. Decadal changes in summer mortality in U.S. cities.  Int J Biometeorol. 2003;  47 166-175
• 378 Jorgensen J H, Crawford S A, McElmeel M L, Whitney C G. Activities of cethromycin and telithromycin against recent North American isolates of Streptococcus pneumoniae .  Antimicrob Agents Chemother. 2004;  48 605-607
• 379 Davies T A, Kelly L M, Jacobs M R, Appelbaum P C. Antipneumococcal activity of telithromycin by agar dilution, microdilution, E test, and disk diffusion methodologies.  J Clin Microbiol. 2000;  38 1444-1448
• 380 Reinert R R, Bryskier A, Lutticken R. In vitro activities of the new ketolide antibiotics HMR 3004 and HMR 3647 against Streptococcus pneumoniae in Germany.  Antimicrob Agents Chemother. 1998;  42 1509-1511
• 381 Morrissey I, Farrell D J, Bakker S, Buckridge S, Felmingham D. Molecular characterization and antimicrobial susceptibility of fluoroquinolone-resistant or -susceptible Streptococcus pneumoniae from Hong Kong.  Antimicrob Agents Chemother. 2003;  47 1433-1435
• 382 Felmingham D. Microbiological profile of telithromycin, the first ketolide antimicrobial.  Clin Microbiol Infect. 2001;  7(Suppl 3) 2-10
• 383 Farrell D J, Felmingham D. Activities of telithromycin against 13,874 Streptococcus pneumoniae isolates collected between 1999 and 2003.  Antimicrob Agents Chemother. 2004;  48 1882-1884
• 384 Stratton C W, Brown S D. Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against community-acquired bacterial respiratory tract pathogens in the United States: findings from the PROTEKT US study, 2000-2001.  Clin Ther. 2004;  26 522-530
• 385 Pankuch G A, Visalli M A, Jacobs M R, Appelbaum P C. Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents.  Antimicrob Agents Chemother. 1998;  42 624-630
• 386 Odenholt I, Lowdin E, Cars O. Pharmacodynamics of telithromycin in vitro against respiratory tract pathogens.  Antimicrob Agents Chemother. 2001;  45 23-29
• 387 Jacobs M R, Bajaksouzian S, Appelbaum P C. Telithromycin post-antibiotic and post-antibiotic sub-MIC effects for 10 gram-positive cocci.  J Antimicrob Chemother. 2003;  52 809-812
• 388 Shortridge V D, Zhong P, Cao Z et al.. Comparison of in vitro activities of ABT-773 and telithromycin against macrolide-susceptible and -resistant streptococci and staphylococci.  Antimicrob Agents Chemother. 2002;  46 783-786
• 389 Perez-Trallero E, Marimon J M, Iglesias L, Larruskain J. Fluoroquinolone and macrolide treatment failure in pneumococcal pneumonia and selection of multidrug-resistant isolates.  Emerg Infect Dis. 2003;  9 1159-1162
• 390 Zhanel G G, Wierzbowski A K, Hisanaga P, Hoban D J. The use of ketolides in treatment of upper respiratory tract infections.  Curr Infect Dis Rep. 2004;  6 191-199
• 391 Tellier G, Chang J R, Asche C V, Lavin B, Stewart J, Sullivan S D. Comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days.  Curr Med Res Opin. 2004;  20 739-747
• 392 Niederman M S, Chang J R, Stewart J, Nusrat R, Nieman R B. Comparison of hospitalization rates in patients with community-acquired pneumonia treated with 10 days of telithromycin or clarithromycin.  Curr Med Res Opin. 2004;  20 749-756
• 393 Niederman M S, Mandell L A, Anzueto A et al.. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention.  Am J Respir Crit Care Med. 2001;  163 1730-1754
• 394 Mandell L A, Marrie T J, Grossman R F, Chow A W, Hyland R H. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group.  Clin Infect Dis. 2000;  31 383-421
• 395 Mandell L A, Bartlett J G, Dowell S F, File Jr T M, Musher D M, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults.  Clin Infect Dis. 2003;  37 1405-1433
• 396 Zervos M J, Hershberger E, Nicolau D P et al.. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000.  Clin Infect Dis. 2003;  37 1643-1648
• 397 Ena J, Lopez-Perezagua M M, Martinez-Peinado C, Cia-Barrio M A, Ruiz-Lopez I. Emergence of ciprofloxacin resistance in Escherichia coli isolates after widespread use of fluoroquinolones.  Diagn Microbiol Infect Dis. 1998;  30 103-107
• 398 Paterson D L, Mulazimoglu L, Casellas J M et al.. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia.  Clin Infect Dis. 2000;  30 473-478
• 399 Saurina G, Quale J M, Manikal V M, Oydna E, Landman D. Antimicrobial resistance in Enterobacteriaceae in Brooklyn, NY: epidemiology and relation to antibiotic usage patterns.  J Antimicrob Chemother. 2000;  45 895-898
• 400 Thomson C J. The global epidemiology of resistance to ciprofloxacin and the changing nature of antibiotic resistance: a 10 year perspective.  J Antimicrob Chemother. 1999;  43(Suppl A) 31-40
• 401 de la Campa A G, Ferrandiz M J, Tubau F, Pallares R, Manresa F, Linares J. Genetic characterization of fluoroquinolone-resistant Streptococcus pneumoniae strains isolated during ciprofloxacin therapy from a patient with bronchiectasis.  Antimicrob Agents Chemother. 2003;  47 1419-1422
• 402 Perez-Trallero E, Garcia-Arenzana J M, Jimenez J A, Peris A. Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumonia treated with ciprofloxacin.  Eur J Clin Microbiol Infect Dis. 1990;  9 905-906
• 403 Barry A L, Brown S D, Fuchs P C. Fluoroquinolone resistance among recent clinical isolates of Streptococcus pneumoniae .  J Antimicrob Chemother. 1999;  43 428-429
• 404 Ho P L, Tse W S, Tsang K W et al.. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study.  Clin Infect Dis. 2001;  32 701-707
• 405 Scheld W M. Maintaining fluoroquinolone class efficacy: review of influencing factors.  Emerg Infect Dis. 2003;  9 1-9
• 406 Lim S, Bast D, McGeer A, de Azavedo J, Low D E. Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance.  Emerg Infect Dis. 2003;  9 833-837
• 407 Brueggemann A B, Coffman S L, Rhomberg P et al.. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.  Antimicrob Agents Chemother. 2002;  46 680-688
• 408 NCCLS .Performance Standards for Antimicrobial Susceptibility Testing. 14th Information Supplement, M100-S14. Wayne, PA; NCCLS 2004
• 409 Zhanel G G, Ennis K, Vercaigne L et al.. A critical review of the fluoroquinolones: focus on respiratory infections.  Drugs. 2002;  62 13-59
• 410 Bast D J, Low D E, Duncan C L et al.. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance.  Antimicrob Agents Chemother. 2000;  44 3049-3054
• 411 Munoz R, De La Campa A G. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype.  Antimicrob Agents Chemother. 1996;  40 2252-2257
• 412 Fernandez-Moreira E, Balas D, Gonzalez I, de la Campa A G. Fluoroquinolones inhibit preferentially Streptococcus pneumoniae DNA topoisomerase IV than DNA gyrase native proteins.  Microb Drug Resist. 2000;  6 259-267
• 413 Pan X S, Fisher L M. Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones.  Antimicrob Agents Chemother. 1999;  43 1129-1136
• 414 Perichon B, Tankovic J, Courvalin P. Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae .  Antimicrob Agents Chemother. 1997;  41 1166-1167
• 415 Davies T A, Evangelista A, Pfleger S, Bush K, Sahm D F, Goldschmidt R. Prevalence of single mutations in topoisomerase type II genes among levofloxacin-susceptible clinical strains of Streptococcus pneumoniae isolated in the United States in 1992 to 1996 and 1999 to 2000.  Antimicrob Agents Chemother. 2002;  46 119-124
• 416 Piddock L J, Johnson M M, Simjee S, Pumbwe L. Expression of efflux pump gene pmrA in fluoroquinolone-resistant and -susceptible clinical isolates of Streptococcus pneumoniae .  Antimicrob Agents Chemother. 2002;  46 808-812
• 417 Smith H J, Walters M, Hisanaga T, Zhanel G G, Hoban D J. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.  Antimicrob Agents Chemother. 2004;  48 3954-3958
• 418 Kupronis B A, Richards C L, Whitney C G. Invasive pneumococcal disease in older adults residing in long-term care facilities and in the community.  J Am Geriatr Soc. 2003;  51 1520-1525
• 419 Black J, Moland E S, Chartrand S A, Thomson K S. Activity of oral agents against pediatric isolates of Streptococcus pneumoniae .  Diagn Microbiol Infect Dis. 2001;  39 195-197
• 420 Thomson K S, Chartrand S A, Sanders C C, Block S L. Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae .  Antimicrob Agents Chemother. 1997;  41 478-480
• 421 Nuermberger E L, Bishai W R. Antibiotic resistance in Streptococcus pneumoniae: what does the future hold?.  Clin Infect Dis. 2004;  38(Suppl 4) S363-S371
• 422 Tillotson G S, Zhao X, Drlica K. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.  N Engl J Med. 2002;  347 65-67 , author reply 7
• 423 Goldsmith C E, Moore J E, Murphy P G, Ambler J E. Increased incidence of ciprofloxacin resistance in penicillin-resistant pneumococci in Northern Ireland.  J Antimicrob Chemother. 1998;  41 420-421
• 424 Linares J, de la Campa A G, Pallares R. Fluoroquinolone resistance in Streptococcus pneumoniae .  N Engl J Med. 1999;  341 1546-1547 , author reply 7-8
• 425 Garcia-Rey C, Aquilar L, Baquero F. Influences of different factors on prevalence of ciprofloxacin resistance in Streptococcus pneumoniae in Spain.  Antimicrob Agents Chemother. 2000;  44 3481-3482
• 426 Nagai K, Appelbaum P C, Davies T A et al.. Susceptibilities to telithromycin and six other agents and prevalence of macrolide resistance due to L4 ribosomal protein mutation among 992 pneumococci from 10 central and eastern European countries.  Antimicrob Agents Chemother. 2002;  46 371-377
• 427 Jones M E, Blosser-Middleton R S, Critchley I A, Karlowsky J A, Thornsberry C, Sahm D F. In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000-2001.  Clin Microbiol Infect. 2003;  9 590-599
• 428 Chiu S S, Ho P L, Chow F K, Yuen K Y, Lau Y L. Nasopharyngeal carriage of antimicrobial-resistant Streptococcus pneumoniae among young children attending 79 kindergartens and day care centers in Hong Kong.  Antimicrob Agents Chemother. 2001;  45 2765-2770
• 429 Jones R N, Pfaller M A. Macrolide and fluoroquinolone (levofloxacin) resistances among Streptococcus pneumoniae strains: significant trends from the SENTRY Antimicrobial Surveillance Program (North America, 1997-1999).  J Clin Microbiol. 2000;  38 4298-4299
• 430 Pottumarthy S, Fritsche T R, Sader H S, Stilwell M G, Jones R N. Susceptibility patterns of Streptococcus pneumoniae isolates in North America (2002-2003): contemporary in vitro activities of amoxicillin/clavulanate and 15 other antimicrobial agents.  Int J Antimicrob Agents. 2005;  25 282-289
• 431 Quale J, Landman D, Ravishankar J, Flores C, Bratu S. Streptococcus pneumoniae, Brooklyn, New York: fluoroquinolone resistance at our doorstep.  Emerg Infect Dis. 2002;  8 594-597
• 432 Bhavnani S, P H, Jones R N et al.. Relationship between increased levofloxacin use and decreased susceptibility to Streptococcus pneumonia: report from the ARREST Program {abstract K-1397}. In: Program and Abstracts of the 43rd International Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; American Society for Microbiologym 2003
• 433 Simor A E, Louie M, Low D E. Canadian national survey of prevalence of antimicrobial resistance among clinical isolates of Streptococcus pneumoniae. Canadian Bacterial Surveillance Network.  Antimicrob Agents Chemother. 1996;  40 2190-2193
• 434 Perez-Trallero E, Garcia-Rey C, Martin-Sanchez A M, Aguilar L, Garcia-de-Lomas J, Ruiz J. Activities of six different quinolones against clinical respiratory isolates of Streptococcus pneumoniae with reduced susceptibility to ciprofloxacin in Spain.  Antimicrob Agents Chemother. 2002;  46 2665-2667
• 435 Zhanel G G, Walkty A, Nichol K, Smith H, Noreddin A, Hoban D J. Molecular characterization of fluoroquinolone resistant Streptococcus pneumoniae clinical isolates obtained from across Canada.  Diagn Microbiol Infect Dis. 2003;  45 63-67
• 436 Ip M, Lyon D J, Yung R W, Chan C, Cheng A F. Evidence of clonal dissemination of multidrug-resistant Streptococcus pneumoniae in Hong Kong.  J Clin Microbiol. 1999;  37 2834-2839
• 437 McGee L, Goldsmith C E, Klugman K P. Fluoroquinolone resistance among clinical isolates of Streptococcus pneumoniae belonging to international multiresistant clones.  J Antimicrob Chemother. 2002;  49 173-176
• 438 Canton R, Morosini M, Enright M C, Morrissey I. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme.  J Antimicrob Chemother. 2003;  52 944-952
• 439 Perez-Trallero E, Marimon J M, Gonzalez A, Iglesias L. Spain14-5 international multiresistant Streptococcus pneumoniae clone resistant to fluoroquinolones and other families of antibiotics.  J Antimicrob Chemother. 2003;  51 715-719
• 440 Ambrose P G, Bhavnani S M, Owens Jr R C. Clinical pharmacodynamics of quinolones.  Infect Dis Clin North Am. 2003;  17 529-543
• 441 Fukuda H, Kishii R, Takei M, Hosaka M. Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae .  Antimicrob Agents Chemother. 2001;  45 1649-1653
• 442 Jones R N, Rubino C M, Bhavnani S M, Ambrose P G. Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team.  Antimicrob Agents Chemother. 2003;  47 292-296
• 442a Noreddin A M, Marras T K, Sanders K, Chan C KN, Hoban D J, Zhanel G G. Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P), and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP).  Int J Antimicrob Agents. 2004;  24 479-484
• 443 Dalhoff A, Krasemann C, Wegener S, Tillotson G. Penicillin-resistant Streptococcus pneumoniae: review of moxifloxacin activity.  Clin Infect Dis. 2001;  32(Suppl 1) S22-S29
• 444 Coyle E A, Kaatz G W, Rybak M J. Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae .  Antimicrob Agents Chemother. 2001;  45 1654-1659
• 445 MacGowan A P, Rogers C A, Holt H A, Wootton M, Bowker K E. Pharmacodynamics of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model of infection.  Antimicrob Agents Chemother. 2001;  45 2916-2921
• 446 Allen G P, Kaatz G W, Rybak M J. Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model.  Antimicrob Agents Chemother. 2003;  47 2606-2614
• 447 Heaton V J, Ambler J E, Fisher L M. Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro.  Antimicrob Agents Chemother. 2000;  44 3112-3117
• 448 Ince D, Zhang X, Silver L C, Hooper D C. Topoisomerase targeting with and resistance to gemifloxacin in Staphylococcus aureus .  Antimicrob Agents Chemother. 2003;  47 274-282
• 449 Fukuda H, Hiramatsu K. Primary targets of fluoroquinolones in Streptococcus pneumoniae .  Antimicrob Agents Chemother. 1999;  43 410-412
• 450 Gillespie S H, Voelker L L, Ambler J E, Traini C, Dickens A. Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation.  Microb Drug Resist. 2003;  9 17-24
• 451 Smith H J, Noreddin A M, Siemens C G et al.. Designing fluoroquinolone breakpoints for Streptococcus pneumoniae by using genetics instead of pharmacokinetics-pharmacodynamics.  Antimicrob Agents Chemother. 2004;  48 3630-3635
• 452 MacGowan A P, Bowker K E. Mechanism of fluoroquinolone resistance is an important factor in determining the antimicrobial effect of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model.  Antimicrob Agents Chemother. 2003;  47 1096-1100
• 453 Tillotson G, Zhao X, Drlica K. Fluoroquinolones as pneumococcal therapy: closing the barn door before the horse escapes.  Lancet Infect Dis. 2001;  1 145-146
• 454 Ambrose P G, Grasela D M. The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae .  Diagn Microbiol Infect Dis. 2000;  38 151-157
• 455 MacGowan A P, Rogers C A, Holt H A, Bowker K E. Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model.  Antimicrob Agents Chemother. 2003;  47 1088-1095
• 456 Ambrose P G, Grasela D M, Grasela T H, Passarell J, Mayer H B, Pierce P F. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections.  Antimicrob Agents Chemother. 2001;  45 2793-2797
• 457 Lister P D, Sanders C C. Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae .  J Antimicrob Chemother. 2001;  47 811-818
• 458 Blondeau J M, Zhao X, Hansen G, Drlica K. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae .  Antimicrob Agents Chemother. 2001;  45 433-438
• 459 Khodursky A B, Cozzarelli N R. The mechanism of inhibition of topoisomerase IV by quinolone antibacterials.  J Biol Chem. 1998;  273 27668-27677
• 460 Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies.  Clin Infect Dis. 2001;  33(Suppl 3) S147-S156
• 461 Sindelar G, Zhao X, Liew A et al.. Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria.  Antimicrob Agents Chemother. 2000;  44 3337-3343
• 462 Wortmann G W, Bennett S P. Fatal meningitis due to levofloxacin-resistant Streptococcus pneumoniae .  Clin Infect Dis. 1999;  29 1599-1600
• 463 Kays M B, Smith D W, Wack M E, Denys G A. Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia.  Pharmacotherapy. 2002;  22 395-399
• 464 Empey P E, Jennings H R, Thornton A C, Rapp R P, Evans M E. Levofloxacin failure in a patient with pneumococcal pneumonia.  Ann Pharmacother. 2001;  35 687-690
• 465 Ross J J, Worthington M G, Gorbach S L. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.  N Engl J Med. 2002;  347 65-67 , author reply 7
• 466 Kuehnert M J, Nolte F S, Perlino C A. Fluoroquinolone resistance in Streptococcus pneumoniae .  Ann Intern Med. 1999;  131 312-313
• 467 Anderson K B, Tan J S, File Jr T M, DiPersio J R, Willey B M, Low D E. Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia.  Clin Infect Dis. 2003;  37 376-381
• 468 Pletz M W, McGee L, Burkhardt O, Lode H, Klugman K P. Ciprofloxacin treatment failure in a patient with resistant Streptococcus pneumoniae infection following prior ciprofloxacin therapy.  Eur J Clin Microbiol Infect Dis. 2005;  24 58-60
• 469 Roson B, Carratala J, Fernandez-Sabe N, Tubau F, Manresa F, Gudiol F. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia.  Arch Intern Med. 2004;  164 502-508
• 470 Fuller J D, Low D E. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance.  Clin Infect Dis. 2005;  41 118-121
• 471 Fluit A C, Florijn A, Verhoef J, Milatovic D. Presence of tetracycline resistance determinants and susceptibility to tigecycline and minocycline.  Antimicrob Agents Chemother. 2005;  49 1636-1638
• 472 Seral C, Castillo F J, Rubio-Calvo M C, Fenoll A, Garcia C, Gomez-Lus R. Distribution of resistance genes tet(M), aph3′-III, catpC194 and the integrase gene of Tn1545 in clinical Streptococcus pneumoniae harbouring erm(B) and mef(A) genes in Spain.  J Antimicrob Chemother. 2001;  47 863-866
• 473 Jenkins S G, Farrell D J, Patel M, Lavin B S. Trends in anti-bacterial resistance among Streptococcus pneumoniae isolated in the USA, 2000-2003: PROTEKT US years 1-3.  J Infect. 2005; 
• 474 Erdem H, Pahsa A. Antibiotic resistance in pathogenic Streptococcus pneumoniae isolates in Turkey.  J Chemother. 2005;  17 25-30
• 475 Jones R N, Sader H S, Fritsche T R. Doxycycline use for community-acquired pneumonia: contemporary in vitro spectrum of activity against Streptococcus pneumoniae (1999-2002).  Diagn Microbiol Infect Dis. 2004;  49 147-149
• 476 Zarakolu P, Soyletir G, Gur D, Unal S. Antimicrobial resistance patterns of respiratory pathogens: a local report from Turkey.  Clin Microbiol Infect. 2003;  9 1257-1258
• 477 Novak R, Henriques B, Charpentier E, Normark S, Tuomanen E. Emergence of vancomycin tolerance in Streptococcus pneumoniae .  Nature. 1999;  399 590-593
• 478 McCullers J A, English B K, Novak R. Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae from the cerebrospinal fluid of a patient who developed recrudescent meningitis.  J Infect Dis. 2000;  181 369-373
• 479 Henriques Normark B, Novak R, Ortqvist A, Kallenius G, Tuomanen E, Normark S. Clinical isolates of Streptococcus pneumoniae that exhibit tolerance of vancomycin.  Clin Infect Dis. 2001;  32 552-558
• 480 Cha R, Rybak M J. Linezolid and vancomycin, alone and in combination with rifampin, compared with moxifloxacin against a multidrug-resistant and a vancomycin-tolerant Streptococcus pneumoniae strain in an in vitro pharmacodynamic model.  Antimicrob Agents Chemother. 2003;  47 1984-1987
• 481 Rodriguez-Cerrato V, McCoig C C, Saavedra J et al.. Garenoxacin (BMS-284756) and moxifloxacin in experimental meningitis caused by vancomycin-tolerant pneumococci.  Antimicrob Agents Chemother. 2003;  47 211-215
• 482 Bradley J S, Scheld W M. The challenge of penicillin-resistant Streptococcus pneumoniae meningitis: current antibiotic therapy in the 1990s.  Clin Infect Dis. 1997;  24(Suppl 2) S213-S221
• 483 Martinez-Lacasa J, Cabellos C, Martos A et al.. Experimental study of the efficacy of vancomycin, rifampicin and dexamethasone in the therapy of pneumococcal meningitis.  J Antimicrob Chemother. 2002;  49 507-513
• 484 Marchese A, Mannelli S, Tonoli E, Gorlero F, Toni M, Schito G C. Prevalence of antimicrobial resistance in Streptococcus pneumoniae circulating in Italy: results of the Italian Epidemiological Observatory Survey (1997-1999).  Microb Drug Resist. 2001;  7 277-287
• 485 Ferrandiz M J, Ardanuy C, Linares J et al.. New mutations and horizontal transfer of rpoB among rifampin-resistant Streptococcus pneumoniae from four Spanish hospitals.  Antimicrob Agents Chemother. 2005;  49 2237-2245
• 486 Restrepo M I, Velez J A, McElmeel M L, Whitney C G, Jorgensen J H. Activity of daptomycin against recent North American isolates of Streptococcus pneumoniae .  Antimicrob Agents Chemother. 2003;  47 2974-2977
• 487 Spangler S K, Jacobs M R, Appelbaum P C. Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci.  Antimicrob Agents Chemother. 1996;  40 481-484
• 488 Jones R N, Farrell D J, Morrissey I. Quinupristin-dalfopristin resistance in Streptococcus pneumoniae: novel L22 ribosomal protein mutation in two clinical isolates from the SENTRY antimicrobial surveillance program.  Antimicrob Agents Chemother. 2003;  47 2696-2698
• 489 Barry A L, Fuchs P C, Brown S D. In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers.  Antimicrob Agents Chemother. 2001;  45 1919-1922
• 490 Snydman D R, Jacobus N V, McDermott L A, Lonks J R, Boyce J M. Comparative in vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens.  Antimicrob Agents Chemother. 2000;  44 3447-3450
• 491 Fluit A C, Schmitz F J, Verhoef J, Milatovic D. In vitro activity of daptomycin against gram-positive European clinical isolates with defined resistance determinants.  Antimicrob Agents Chemother. 2004;  48 1007-1011
• 492 Cottagnoud P, Pfister M, Acosta F et al.. Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis.  Antimicrob Agents Chemother. 2004;  48 3928-3933
• 493 Critchley I A, Blosser-Middleton R S, Jones M E, Thornsberry C, Sahm D F, Karlowsky J A. Baseline study to determine in vitro activities of daptomycin against gram-positive pathogens isolated in the United States in 2000-2001.  Antimicrob Agents Chemother. 2003;  47 1689-1693
• 494 Pankuch G A, Davies T A, Jacobs M R, Appelbaum P C. Antipneumococcal activity of ertapenem (MK-0826) compared to those of other agents.  Antimicrob Agents Chemother. 2002;  46 42-46
• 495 Cottagnoud P, Pfister M, Cottagnoud M, Acosta F, Tauber M G. Activities of ertapenem, a new long-acting carbapenem, against penicillin-sensitive or -resistant pneumococci in experimental meningitis.  Antimicrob Agents Chemother. 2003;  47 1943-1947
• 496 Fasola E, Spangler S K, Ednie L M, Jacobs M R, Bajaksouzian S, Appelbaum P C. Comparative activities of LY 333328, a new glycopeptide, against penicillin-susceptible and -resistant pneumococci.  Antimicrob Agents Chemother. 1996;  40 2661-2663
• 497 Cabellos C, Fernandez A, Maiques J M et al.. Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis.  Antimicrob Agents Chemother. 2003;  47 1907-1911
• 498 Zhanel G G, Homenuik K, Nichol K et al.. The glycylcyclines: a comparative review with the tetracyclines.  Drugs. 2004;  64 63-88
• 499 Kitzis M D, Ly A, Goldstein F W. In vitro activities of tigecycline (GAR-936) against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae .  Antimicrob Agents Chemother. 2004;  48 366-367
• 500 Henrichsen J. Six newly recognized types of Streptococcus pneumoniae .  J Clin Microbiol. 1995;  33 2759-2762
• 501 Feikin D R, Klugman K P. Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines.  Clin Infect Dis. 2002;  35 547-555
• 502 Hausdorff W P, Bryant J, Paradiso P R, Siber G R. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.  Clin Infect Dis. 2000;  30 100-121
• 503 Whitney C G, Farley M M, Hadler J et al.. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.  N Engl J Med. 2003;  348 1737-1746
• 504 Pelton S I. The decline in invasive pneumococcal disease.  Pediatrics. 2004;  113(3 Pt 1) 617-618
• 505 Kaplan S L, Mason Jr E O, Wald E R et al.. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine.  Pediatrics. 2004;  113(3 Pt 1) 443-449
• 506 Talbot T R, Poehling K A, Hartert T V et al.. Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in Tennessee after introduction of the pneumococcal conjugate vaccine.  Clin Infect Dis. 2004;  39 641-648
• 507 Dagan R, Givon-Lavi N, Zamir O et al.. Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers.  J Infect Dis. 2002;  185 927-936
• 508 Jackson L A, Neuzil K M, Yu O et al.. Effectiveness of pneumococcal polysaccharide vaccine in older adults.  N Engl J Med. 2003;  348 1747-1755
• 509 Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).  MMWR Recomm Rep. 1997;  46(RR-8) 1-24
• 510 Shapiro E D, Berg A T, Austrian R et al.. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.  N Engl J Med. 1991;  325 1453-1460
• 511 Advisory Committee on Immunization Practice . Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practice (ACIP).  MMWR Recomm Rep. 2000;  49(RR-9) 1-35
• 512 Eskola J, Kilpi T, Palmu A et al.. Efficacy of a pneumococcal conjugate vaccine against acute otitis media.  N Engl J Med. 2001;  344 403-409
• 513 O'Brien K L, Dagan R. The potential indirect effect of conjugate pneumococcal vaccines.  Vaccine. 2003;  21 1815-1825
• 514 McEllistrem M C, Adams J M, Patel K et al.. Acute otitis media due to penicillin-nonsusceptible Streptococcus pneumoniae before and after the introduction of the pneumococcal conjugate vaccine.  Clin Infect Dis. 2005;  40 1738-1744
• 515 Obaro S K, Adegbola R A, Banya W A, Greenwood B M. Carriage of pneumococci after pneumococcal vaccination.  Lancet. 1996;  348 271-272
• 516 Klugman K P, Madhi S A, Huebner R E, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection.  N Engl J Med. 2003;  349 1341-1348
• 517 Madhi S A, Klugman K P. A role for Streptococcus pneumoniae in virus-associated pneumonia.  Nat Med. 2004;  10 811-813
• 518 Dagan R, Givon-Lavi N, Zamir O, Fraser D. Effect of a nonvalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers.  Pediatr Infect Dis J. 2003;  22 532-540
• 519 Givon-Lavi N, Fraser D, Dagan R. Vaccination of day-care center attendees reduces carriage of Streptococcus pneumoniae among their younger siblings.  Pediatr Infect Dis J. 2003;  22 524-532
• 520 Temime L, Guillemot D, Boelle P Y. Short- and long-term effects of pneumococcal conjugate vaccination of children on penicillin resistance.  Antimicrob Agents Chemother. 2004;  48 2206-2213
• 521 Regelmann W E. A pain in the ear: what has the 7-valent conjugated pneumococcal vaccine done to reduce the incidence of acute otitis media?.  Clin Infect Dis. 2005;  40 1745-1747
• 522 Brown R B, Iannini P, Gross P, Kunkel M. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database.  Chest. 2003;  123 1503-1511